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Abstract 
 
Myeloproliferative neoplasms (MPNs) are diseases of hematopoietic stem 
cell origin and are characterized by uncontrolled growth of cells of the myeloid 
compartment. The Philadelphia chromosome negative classical MPNs, including 
polycythemia vera, essential thrombocythemia, and myelofibrosis, are diseases 
of dysregulated JAK2 signaling. In fact, the majority of MPN patients have 
activating mutations in JAK2 (e.g JAK2-V617F), a tyrosine kinase that 
contributes to the growth and survival of myeloid cells. While MPNs were first 
described over sixty years ago, a significant need remains to develop therapeutic 
strategies for them. Inhibitors of JAK2 are currently being developed, and one 
inhibitor, ruxolitinib, was recently approved for certain MPN patients. Ruxolitinib 
has made profound impacts on improving splenomegaly and constitutional 
symptoms in MPN patients, but it and other JAK2 inhibitors have not significantly 
reduced the JAK2 mutant allele burden, and thus such inhibitors have not 
induced remission in these patients. The current consensus in the MPN field 
supports JAK inhibition for the treatment of patients, but a further understanding  
of MPNs and JAK2 signaling, as well as improved JAK2 inhibitors, may be 
necessary for treating MPN patients.  
The work described in this dissertation has uncovered novel requirements 
for JAK2-V617F-driven signaling and transformation. We demonstrate that JAK2-
V617F co-localizes with lipid rafts, cholesterol-rich microdomains within the 
xi 
 
plasma membrane that function to serve as platforms for signaling complex 
formation. Signaling complex formation is a necessary component for 
dysregulated signaling induced by JAK2-V617F. We provide evidence that 
cholesterol altering-lipid raft disrupting agents attenuate JAK2-V617F-driven 
signaling. We also show that cholesterol-lowering statins are effective at 
downregulating JAK2 signaling and inducing apoptosis in JAK2-V617F-driven 
cell lines. Importantly, we show that statins, inhibitors of the mevalonate pathway, 
inhibit the growth of primary MPN cells, while the same statin doses have no 
effect on healthy controls. Impressively, we demonstrate that statins cooperate 
with multiple JAK inhibitors, including ruxolitinib, to inhibit cell growth and induce 
apoptosis of JAK2-V617F-driven cells. 
This report establishes statin-mediated inhibition of the mevalonate 
pathway as a potential approach to improve MPN therapeutics. We propose 
future studies with statins and JAK2 inhibitors in the treatment of MPNs. 
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Chapter 1 
Introduction 
 
Janus Kinases 
Janus kinases, or JAKs, are members of a family of proteins composed of 
four members in humans: JAK1, JAK2, JAK3, and Tyk2 [1-2]. JAK proteins act 
as important signal transducers of cytokine signaling, and have crucial roles in 
normal cellular physiology such as development, proliferation, survival, and 
immune regulation through cytokine signaling [3-5]. Knockout murine models 
highlight the importance of JAK proteins in normal physiology. JAK1 knockout 
mouse models leads to perinatal lethality with severe defects in lymphoid 
development [6]. JAK2 knockout mice are embryonic lethal due to defective 
erythropoiesis, implicating its role in erythropoietin (EPO), thrombopoietin (TPO), 
IL-3, and IL-5 cytokine signaling [7-8]. While JAK3 knockout mice survive, they 
experience severe combined immune deficiency (SCID), due to defects in the B 
and T cell lineages [9]. Finally, Tyk2 knockout mice survive, but have incomplete 
responses to cytokine stimulation [10-11]. JAK1 and JAK2 are ubiquitously 
expressed, while expression of JAK3 and Tyk2 is primarily seen in the lympho-
hematopoietic lineages [12]. 
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JAK Protein Structure 
 The JAK family members contain seven homologous domains known as 
the Janus homology (JH) domains (Figure 1). At the C-terminus is the JH1 
domain, which contains the enzymatic tyrosine kinase region of the protein. The 
JH2 domain is also known as the pseudokinase domain and is similar to the 
kinase domain in structure. The presence of these two “kinase domains” 
provided the inspiration to name these proteins after Janus, the two-faced 
Roman God. The pseudokinase domain, however, does not function as the 
source of the tyrosine kinase activity of JAKs, but instead functions in an auto-
regulatory fashion on the kinase domain. For example, deletion of the 
pseudokinase domain in JAK2 and 3 enhances kinase activity [13-14]. Up until 
recently, it was thought that the pseudokinase domain had no true kinase activity. 
Ungureanu et al. showed the pseudokinase domain is capable of 
phosphorylating two negative regulatory sites, Ser523 and Tyr570 [15]. 
Phosphorylation of Ser523 and Tyr570 results in reduced overall JAK2 kinase 
activity. Bandaranayake et al. in 2012 demonstrated that the pseudokinase 
domain was found to bind Mg-ATP in a non-canonical manner and folds as a 
typical eukaryotic protein kinase [16].  
The JH3 domain of JAKs comprises the Src-homology-2 (SH2)-like 
domain and it is largely not understood how it contributes to JAK activity [17-19], 
although it may play a role in homodimeric interactions of JAK2 kinase [20]. JH4-
7 composes the FERM (band 4.1, ezrin, radixin and moesin) domain and is 
responsible for interaction with the box 1 and 2 motifs on cytokine receptors.  
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Cytokine Receptors and JAKs 
JAKs play a crucial role in cytokine signaling by acting as signal 
transducers of cytokine stimulation [1]. Cytokine receptors are transmembrane 
receptors that harbor no intrinsic kinase activity and rely on JAKs to transduce 
cytokine stimulation signals from the extracellular environment, to ultimately 
induce changes in a cell [21]. Cytokine receptors can be divided into two general 
classification systems, type I and II cytokine receptors.  Type I cytokine 
receptors, also named hemopoietin receptors, share a common amino acid motif, 
WSXWS located in the extracellular domain adjacent to the transmembrane 
domain [22]. Members of the type I receptors family include, but are not limited 
to: Interleukin (IL)-2-7, 9, 11, 12, 13, 15, 21, 23, 27, erythropoietin (EPO), 
granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-colony 
stimulating factor (G-CSF), growth hormone, prolactin, oncostatin M (OSM), and 
 
FERM Pseudokinase Kinase
Interaction 
with 
cytokine 
receptors
Auto-regulatory role-
inhibits 
kinase domain
Functional
kinase
domain
JAK2
33 270 545 805 849 1123
V617FExon 12 
mutations
Figure 1: Schematic of JAK2 protein domains. 
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leukemia inhibitory factor (LIF) receptors [22]. Conversely, type II cytokine 
receptors include, but are not limited to: interferon (INF) alpha, beta, gamma, IL-
10, 20, 22, and 28 receptors. Type II cytokine receptors share sequence 
similarity in the extracellular domain in that that contain tandem duplications of 
immunoglobulin (Ig)-like domains [22]. Cytokine receptors can bind multiple JAK 
family members and because all of these receptors work in dimer or oligomer 
complexes, can form a signaling complex with more than one type of JAK [23]. 
JAK1 and 2 pre-associate with cytokine receptors after final assembly of the 
cytokine receptor at the golgi apparatus and prior to translocation to the plasma 
membrane [24]. The golgi apparatus is also a site where cytokine receptors can 
get post-translational modifications, such as glycosylation [25]. The pre-
associated receptor/JAK complex and post-translational modifications that occur 
at the golgi are thought to promote stability and aid in the transport of these 
receptors to the plasma membrane [26].  
 
Canonical JAK/STAT Signaling 
Once the receptor/JAK complex reaches the membrane, the receptor and 
JAK molecules maintain an inactive confirmation until stimulation by the 
receptor’s cognate ligand (cytokine) [27-28]. Cytokine stimulation induces 
conformational changes in the cytokine receptor, which bring the JAKs on 
adjacent dimer/oligomer receptors in close proximity to transphosphorylate each 
other, setting off a cascade of further signaling events. Once JAK molecules are 
activated, they phosphorylate tyrosines on the receptor, creating docking sites for 
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downstream mediators, such as signal transducer and activator of transcription 
(STAT) molecules.  STAT molecules bind to the phosphorylated receptor, which 
allow for activated JAKs to phosphorylate the STAT molecules. Phosphorylation 
of STATs allows for dimerization of STAT molecules, which allow entry of the 
transcription factors into the nucleus. Once nuclear, STATs bind to their target 
DNA elements and initiate transcription of their target genes [27-28] 
Activation of JAK/STAT signaling also leads to activation of 
phosphotidylinositol-3’-kinase (PI3K) and AKT and ERK pathways, all of which 
contribute to cell proliferation, survival, blocking apoptosis, etc. [29]. 
 
JAK2 JAK2
Cytokine Receptors
(ie. EpoR)
Cytokine
JAK2 JAK2
Inactive
PP
STAT5
P
STAT5
P
STAT5
P
Transcription
ERK
Akt
P
P
Nucleus
Active
ST
AT
5
P
STAT5
PSTAT5
P
Cytokine
STAT5
P STAT5
P
ST
AT
5
PS
TA
T5
P
Figure 2: Canonical JAK2/STAT Signaling Pathway. Without 
cytokine stimulation pre-associated JAK2 and cytokine receptor 
complex localize to the plasma membrane in an inactive conformation. 
Upon cytokine stimulation, conformational changes in receptors bring 
JAKs in close proximity to transphosphorylate each other. Downstream 
mediators, such as STATs get activated and induce expression of 
STAT target genes. ERK and Akt pathways activation also occurs with 
JAK2 signaling. 
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Negative Regulation of Canonical JAK/STAT Signaling 
 There are a variety of negative regulatory mechanisms to control 
JAK/STAT signaling, including suppressors of cytokine signaling (SOCS) 
proteins, phosphatases, and protein inhibitors of activated STATs (PIAS) [30-31]. 
There are eight SOCS family members, SOCS1-8, that function in a classical 
negative feedback loop, whereby activation of JAK/STAT signaling leads to the 
expression of SOCS proteins. The SOCS family of proteins functions, in large 
part by targeting proteins for degradation through formation of an E3 ubiquitin 
complex [32]. All SOCS proteins contain an SH2 domain and a SOCS box, the 
latter functions to interact with Elongin B/C and Cullin 5, altogether completing an 
E3 ubiquitin complex [33-34]. However, there are additional roles associated with 
SOCS proteins. SOCS1 and 3 contain kinase inhibitory regions (KIRs) that bind 
to the kinase region of JAKs, competing with ATP and blocking kinase activity 
[35]. It has also been described that SOCS proteins, using their SH2 domains, 
bind to the same sites as downstream mediators, thus competing for binding 
sites and downregulating the signaling cascade [33-34]. Phosphatases including 
SH2 domain protein tyrosine phosphatase-2 (SHP-2), SHP-1, CD45, protein 
tyrosine phosphatase1B (PTP1B), and T cell PTP, among others are also 
important in de-activating components of the JAK/STAT pathway by removal of 
phosphate groups [36]. Finally, the PIAS proteins include at least four members 
in humans, PIAS1-4. PIAS proteins not only inhibit STAT molecules, but other 
proteins, namely other transcription factors [37]. PIAS proteins function to target 
proteins for degradation by forming complexes with small ubiquitin-related 
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modifer1 (SUMO1) and an E2 conjugase. However, PIAS proteins not only target 
transcription factors for degradation, but also act to recruit co-regulators that can 
block DNA binding sites, and hence transcription [37].  
 
Non-canonical JAK Signaling 
 JAK signaling has been largely defined by its activity with cytokine 
receptors at the plasma membrane, transducing signaling from cytokine 
stimulation. Recently, however, JAK2 has been shown to also localize and 
function in the nucleus [38]. JAK1 and 2 were shown to phosphorylate tyrosine 
41 of histone H3 (H3Y41), which blocks heterochromatin protein 1 alpha (HP 1α) 
from binding to this histone region. The complete implications of dual localization 
of JAKs in the cytoplasm and nucleus are not yet fully known, however, studies 
by Dawson et al. did provide evidence of nuclear JAK2 activity regulating the 
expression of the lmo2 gene, an oncogene found in hematopoietic cells. This 
implicates JAK2-mediated gene expression alteration by direct histone 
modification. JAK2 inhibition by a small molecule inhibitor, led to a decrease in 
lmo2 mRNA that correlated with a decrease in phosphorylated H3Y41 and an 
increase in HP 1α binding at this locus, providing the first evidence of nuclear 
JAK2 contributing to alteration of gene expression [38]. Thus, direct roles of JAKs 
outside of cytoplasmic signaling are expanding to include nuclear events such as 
histone modification and gene expression. 
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JAK/STAT Pathway Mutations in Humans 
 Due to the role the JAK/STAT pathway has on promoting proliferation, 
survival, differentiation, and immunological responses, it is no surprise that this 
signaling cascade is aberrantly regulated in many human diseases, including 
cancer, hyper IgE syndrome, and severe combined immune deficiency [39]. This 
pathway is fundamental in blood cell production and function, and thus is found 
commonly mutated in hematologic malignancies including leukemia, lymphoma, 
multiple myeloma, and MPNs [29]. Activating mutations (including point 
mutations and chromosomal translocations) in JAK1, 2, and 3 are present in 
such malignancies [40-43]. While STAT activation is central to both wild-type and 
dysregulated JAK activity, STAT mutations are rare to date [29]. Some patients 
with large granular lymphocytic leukemia or lymphoproliferative disorders have 
mutated STAT-3 [44], while mutations in STAT-6 have been found in patients 
with primary mediastinal B-cell lymphoma [45]. Additional activating mutations 
that promote JAK/STAT signaling are found in receptor tyrosine kinases and 
cytokine receptors, including: FLT3 (found in AML) [46], KIT (AML) [47], IL-7R 
(acute lymphoblastic leukemia, ALL) [48-49], GCSF-R (AML, neutroplilia) [50-51], 
and CRLF2 (ALL) [52-53]. 
 Conversely, inactivating JAK/STAT pathway mutations can be found in 
patients with myeloid malignancies. Negative regulators including: LNK 
(MPN/MDS) [54], SOCS1 (Hodgkin lymphoma [55], MPNs [56], mediastinal 
lymphoma [57], PTPN1/2 (T-cell ALL) [58], CD45 (T-cell ALL) [59], and CBL 
(MPNs) [60] have been reported.  
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Myeloproliferative Neoplasms  
MPNs are a group of related hematopoietic stem cell malignancies 
characterized by clonal expansion of the myeloid compartment. MPNs were first 
described as group of related blood disorders by William Dameshek in 1951 [61]. 
Specifically, Dameshek grouped chronic myelogenous leukemia (CML), 
polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) 
and he believed these disorders had their origin in defective bone marrow, with 
the potential to transform to myelodysplastic syndrome (MDS) or acute myeloid 
leukemia (AML). It was also suggested by Dameshek that there may be an 
underlying genetic commonality to these phenotypically distinct MPNs [61]. With 
the discovery of the Philadelphia (Ph) chromosome in CML [62-63], MPNs were 
divided into Ph-positive (CML) and Ph-negative (PV, ET, and MF) MPNs. 
Subsequently, more hematologic disorders have been classified with Ph-negative 
MPNs, including erythroleukemia, but PV, ET, and MF remain classified together 
as the classical MPNs [29, 64-65]. For the purposes of this report, the term ‘MPN’ 
refers to the classical Ph-negative MPNs, PV, ET, and MF.  
MPNs are characterized by an overproduction of mature myeloid cells. 
MPNs can be deadly on their own due to an increased risk of cardiovascular 
events (stroke, heart attack), progression to MF, and bone marrow failure. 
Importantly, MPNs can transform into AML at which point myeloid differentiation 
is compromised [65]. More details of these diseases will be presented in 
forthcoming sections. 
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JAK2-V617F 
 In 2005, five independent groups identified a common somatic mutation in 
the JAK2 gene, this mutation leads to a substitution of valine to a phenylalanine 
at amino acid residue 617 (JAK2-V617F). The JAK2-V617F mutation is highly 
prevalent in the classical MPNs with >95% of PV, 56-60% of ET, and 50% of MF 
patients harboring this mutation [66-70]. With this level of prevalence, the JAK2-
V617F mutation is now incorporated into the diagnoses of these diseases. The 
high prevalence of this JAK2 mutation in MPNs highly suggests it plays a 
causative role in these diseases.   
 
 
 
 
 
 
 
 
 
 
 
Importantly, JAK2-V617F has been shown to be necessary and sufficient 
to induce an MPN phenotype in mice [71], further suggesting it plays a role in 
MPN development. A current hypothesis in the field is that JAK2-V617F gene 
Ph- Classical MPNs
Essential thrombocythemia (ET)
Myelofibrosis (MF)
Polycythemia vera (PV)
Fibrosis of the bone marrow
Expansion of platelets
Expansion of red blood cells
Disease Characteristics Frequency of JAK2-V617F
50% VF+
50-60% VF+
95% VF+
Figure 3: Characterization of Ph- classical MPNs. Table describes the 
major defining disease characteristics and prevalence of the JAK2-V617F 
mutation among Philadelphia chromosome negative (Ph-) classical MPNs, 
polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis 
(MF).  
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dosage contributes to the disease phenotype. That is, high JAK2-V617F 
expression leads to a PV phenotype, while low expression contributes to an ET 
phenotype, and an intermediate level contributes to MF. Interestingly, JAK2-
V617F homozygosity is only found in PV and data from mouse models support 
this gene dosage hypothesis [71].  
            The V617F mutation is located in the pseudokinase domain of JAK2. 
Bandaranayake et al. recently resolved the crystal structure for the pseudokinase 
domain of both wild-type and JAK2-V617F. This work concluded there is a more 
rigid alpha-helix C in the N-lobe in the V617F mutant pseudokinase domain 
compared to the wild-type pseudokinase domain [16], providing a possible 
explanation for dysregulation of the JAK2-V617F mutant. It is proposed that this 
rigid alpha-helix C formation would allow for enhanced transphosphorylation of 
JAK molecules. This is presumably because of a decreased ability of the 
pseudokinase domain to interact with the activation loop of the kinase domain, 
which has been proposed by molecular dynamic simulations [16]. Additionally, 
the mutation of amino acid 617 to phenylalanine leads to π stacking interaction 
with the nearby F595, and this interaction plays a role in the elevated activation 
state of JAK2-V617F [72]. However, even though JAK2-V617F has elevated 
kinase activity due to the V617F mutation, it still requires the presence of a 
cytokine receptor to signal [73]. Cytokine receptors presumably provide a 
scaffolding function for JAK2-V617F proteins to interact and transphosphorylate 
each other, as well as to phosphorylate docking sites on the receptor to recruit 
signal transducers (Figure 4).    
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Other Mutations in MPNs 
There is impressive evidence that JAK2-V617F contributes to MPN 
formation. This includes the high prevalence of the JAK2-V617F mutation in MPN 
patients, the MPN-like disease induced by JAK2-V617F in mouse models, and 
the structural studies of the pseudokinase domain explaining a potential mode of 
dysregulation of JAK2 kinase activity and subsequent signaling [65]. However, 
MPN patients harbor a variety of other activating and inactivating mutations. 
While JAK2-V617F is present in 95% of PV patients, it is estimated that the ~5% 
of PV patients that are JAK2-V617F-negative have mutations in exon 12 of JAK2 
(K539L, etc) [74-75].  These exon 12 mutations have only been identified in PV 
and are thought to result in a similar manner of activation as JAK2-V617F, with 
loss of the auto-regulatory control on the JAK kinase domain [76]. Molecular 
dynamic simulations of JAK2 have suggested this may be caused in part by a 
shift in the salt bridge interaction of amino acid residues D620 and E621 with 
K539 in wild-type JAK2 to R541 in the JAK2 exon 12 mutant H538Q/K539L [77]. 
Activating mutations in MPL (myeloproliferative leukemia virus), also 
known as gene for the thrombopoietin receptor (TpoR) are found in 4% of ET and 
10% of MF patients [78-79]. In particular, substitutions are found at amino acid 
residue 515, where tryptophan is substituted for leucine, lysine, or asparagine. 
These W515 substitutions allow for MPL to maintain an active conformation to 
promote JAK2 activation and signaling in the absence of cytokine stimulation [78-
79].  
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 MPN patients also display mutations in negative regulators of JAK/STAT 
signaling, including LNK, c-CBL, and SOCS proteins [64]. Cytokine stimulation 
(i.e. TPO) promotes the binding of LNK to JAK2, thereby blocking the ability of 
JAK2 to phosphorylate downstream mediators, such as STATs. Inactivating 
mutations in LNK lead to loss of function and subsequent promotion of 
JAK2/STAT signaling [54]. Inactivating mutations have also been identified in 
MPNs and myeloid malignancies in the casitas B-cell lymphoma (c-CBL) protein, 
an E3 ubiquitin ligase that targets components of the JAK/STAT pathway for 
degradation [60].  
 Additionally, a variety of mutations that modify epigenetic regulation are 
found in MPN patients, including mutations in: TET2, IDH1/2, EZH2, ASXL1, and 
DNMT3A [64]. Inactivating mutations in TET2 are found in ~10-15% of MPN 
patients [80-81]. TET2 catalyzes the hydroxylation of 5-methylcytosine, and 
knockdown of TET2 promotes monocyte/macrophage differentiation, implicating 
TET2 with a suppressive effect on the differentiation of myeloid cells [82-83]. The 
isocitrate dehydrogenase1/2 (IDH1/2) enzymes are also mutated in ~4% of MF 
patients [84]. The presence of mutated IDH1/2 suggested predictive value in 
determining the patients that transformed to AML [84]. IDH enzymes function in 
catalyzing the oxidative decarboxylation of isocitrate to produce α-ketoglutarate, 
involved in the citric acid cycle. Rather than producing α-ketoglutarate (αKG), 
cancer cells with mutated IDH1/2 produce 2-hydroxyglutarate (2-HG) [85-86]. 
The switch over of αKG to 2-HG is to the detriment of TET2 because TET2 uses 
αKG as a co-activator. Without αKG, TET2 displays impaired functionality, 
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ultimately affecting methylation and gene expression [29]. MPN patients also 
display inactivating mutations in enhancer of zeste homolog 2 (EZH2) leading to 
methylation and subsequent gene expression changes. EZH2 is a histone 
methyltransferase that functions in conjunction with the polycomb repressor 
complex 2, to alter epigenetic regulation [87]. Additionally, inactivating mutations 
in additional sex combs like 1 (ASXL1), which normally binds to histones and 
alters chromatin remodeling by a mechanism that is not fully elucidated [88]. 
Mutations in DNA methyltransferase 3A (DNMT3A) have also been reported in 
MPNs. Mutated DNMT3A is thought to contribute to epigenetic alteration and 
subsequent gene expression alteration [89]. Multiple modes of dysregulation of 
the JAK2/STAT pathway have been described in MPN patients. Figure 4 depicts 
mechanisms of hematopoietic transformation in MPNs. 
 
The Life of an MPN Patient 
 MPN patients can vary in the severity of myeloid cell expansion. While 
some patients have elevated levels of myeloid cells that do not require 
therapeutic management, others have such a high cellular burden in the 
periphery that management is required and life-threatening [65, 90]. The current 
standard of care does not change the natural history of MPNs. To manage the 
cellular burden, the standard of care includes chemotherapeutic agents such 
hydroxyurea, 2-CDA, and busulfan. Phlebotomy is also used to combat the high 
cellular burden in the periphery. Additional therapies for MPN patients include 
androgens, erythropoietin (EPO), and thalidomide to treat anemia, while 
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lenalidamide and interferon (IFN) pegasys may be given to patients suffering 
from anemia and splenomegaly [91].  
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Figure 4: Mechanisms of JAK2 pathway activation in MPNs. Red 
lightning bolts represent mediators that are dysregulated by mutation in 
MPNs, these include: activating mutations in cytokine receptors (ie. 
MPL), activating JAK2 mutations (JAK2-V617F), inactivating mutations 
in the negative regulator LNK, and mutations in nuclear proteins that 
alter gene expression (i.e. TET2, IDH1/2, DNMT3A, etc.). 
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           Splenomegaly, or enlargement of the spleen, occurs in MPN patients due 
to extramedullary hematopoiesis, or production of blood components 
(hematopoiesis) outside of the bone marrow.Surgery and splenic radiation can 
be used to control splenomegaly [91]. The only potential for a cure in MPN 
patients is through bone marrow transplant. However, since the average age of 
MPN onset is 55, bone marrow transplant is typically not an option because of 
the risk associated with transplant [92]. The current goal with MPN treatment is 
centered around preventing thrombotic events and hemorrhagic complications, 
leading to a lifetime of treatment for many MPN patients [90, 93]. The most 
serious risk for MPN patients includes transformation to acute myeloid leukemia 
(AML), for AML is incurable and thus leads to a dismal prognosis. MPNs can also 
transform into a different MPN. For example, a PV patient can transform to MF 
[93]. It is generally thought that cooperating mutations work with mutations that 
contribute to dysregulated JAK/STAT signaling. Although poorly understood, it is 
hypothesized that the acquisition of particular mutations is what dictates which 
MPN may form as well as the transformation of MPNs from one form to another 
and to AML [64, 93]. Further understanding these genetic and clinical dynamics 
is the goal of ongoing research in the MPN field. 
 
Polycythemia vera 
 PV patients have a primary defect in the erythrocyte lineage, leading to 
expansion of the red blood cells. However, other myeloid cells may also be 
dysregulated and expanded in PV. Untreated PV can be life threatening [65, 94-
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95]. There are approximately 22 new PV cases per 100,000 people in the U.S., 
which accounts for ~68,000 PV patients in the U.S [96-97]. There is a minor male 
predominance (1.2:1) for PV [98]. The median age of diagnosis for PV is 60 
years and is rarely seen in children [98]. The overall mortality of treated PV 
patients is 1.6-1.7 times higher than age/sex-matched healthy individuals [99-
100], with a 15 year survival rate of 65% [99]. A large international study of 1638 
patients showed the leading causes of death for PV patients to include: 
cardiovascular complications (namely thrombosis, stroke, and hemorrhage), solid 
tumors, and leukemic transformation at rates of 45%, 20%, and 13% of deaths, 
respectively [101].   
 
Essential Thrombocythemia 
 The thrombocytic, or platelet, lineage is the primary defective cell lineage 
in ET patients, where expansion of this lineage is seen. Similar to PV, ET 
patients can also display dysregulation and excess production of other myeloid 
lineages [102-104]. The major complications associated with ET include 
thrombosis and hemorrhaging because of the high platelet counts. Approximately 
2% of ET patients transform to AML, while the overall 15 year survival rate for ET 
patients is 73% [99]. It is proposed that ET is the most prevalent Ph- MPN, with 
approximately 24 new ET patients per 100,000 people per year in the U.S, which 
accounts for ~74,000 ET patients in the U.S. [96-97]. 
 
 
  
18 
 
Myelofibrosis 
 MF is considered one of the higher risk and heterogeneous Ph- MPNs 
[105]. MF patients present with a variety of clinical features including: anemia, 
leukocytosis or leucopenia, thrombocytosis or thrombocytopenia, constitutional 
symptoms, and splenomegaly [106]. Importantly, fibrosis, or scarring of the bone 
marrow is a key feature of MF. Depending on the number of risk factors (age >65 
years; hemoglobin <10 g/dL; white blood cell count >25 X 109 /L; peripheral blood 
blasts ≥ 1%; and presence of constitutional symptoms), the survival can be 
predicted [107]. Patients with a low risk have zero risk factors and are expected 
to survive past 11 years. Patients with one risk factor are classified in the 
intermediate-1 group and have a median survival of 8 years. Whereas patients 
with two risk factors are classified in the intermediate-2 group and have a median 
survival of 4 years. High risk patients display ≥ 3 or more risk factors and have a 
median survival of 2 years [107]. MF has an incidence rate of 1.46 people in 
every 100,000 people in the U.S., accounting for 4,500 MF patients in the U.S. 
[97]. 
 
JAK Inhibitors  
 The BCR-ABL inhibitor, imatinib, is highly effective at blocking activity of 
the BCR-ABL oncoprotein, resulting in loss of the transforming signaling and thus 
is highly effective at killing CML cells [108-110]. The imatinib story is one of 
cancers therapy’s best success stories with the five year survival rate being 89%. 
Since 95% of CML patients have the BCR-ABL translocation product, imatinib is 
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a highly successful treatment for CML patients [108-110]. MPNs parallel the CML 
scenario in many regards. A highly prevalent mutation, JAK2-V617F [64], is 
found in the majority of MPN patients, just as in the case of BCR-ABL in CML 
[108-109]. Secondly, murine models were able to recapitulate both MPNs with 
the expression of the single mutation, BCR-ABL recapitulated CML [111], while 
JAK2-V617F recapitulated MPNs [71]. Once the discovery of the JAK2-V617F 
mutation in MPNs was made, it was hoped the field would take a similar path as 
BCR-ABL-targeted imatinib therapy, with JAK inhibitor targeted therapy being 
highly effective for MPN patients. Thus, JAK2 inhibitors were quickly developed 
and moved into clinical trials. 
Many JAK2 inhibitors have been developed including SAR302563, 
CYT387, BMS911543 [94], G6 [112], Z3 [113].  These inhibitors are effective at 
blocking JAK2-V617F-dependent signaling as well as JAK2-V617F-driven MPN 
formation in mice.  Several of these inhibitors have moved into clinical trials and 
the JAK1/2 inhibitor, ruxolitinib, was approved by the FDA in 2011 for use in MF 
patients, just six years after the identification of the JAK2-V617F mutant in 
MPNs. Clinically, JAK inhibitors have demonstrated effectiveness in improving 
quality of life, reducing constitutional symptoms and splenomegaly, but have not 
made significant impacts on reducing the allele burden in MPN patients [94, 114]. 
Thus, these inhibitors have not provided remission of disease in patients. 
However, ruxolitinib use may improve overall survival in high-risk MF patients 
and thus there may be some added benefit in addition to relief of symptomology 
[94]. JAK inhibitors will likely play an important role in the treatment and 
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management of MPNs, but treatment may benefit from combination therapy in 
order to reduce allele burden. Even with the similarities between CML and MPNs, 
it is becoming clearer that MPNs are a more complex disease consisting of 
cooperating mutations in addition to mutations that promote JAK/STAT signaling. 
This is unlike BCR-ABL, which is accepted to be the causative agent in CML 
[115]. Others and we believe that combination therapy of JAK inhibitors with 
additional agents may provide an avenue to reduce allele burden and thus 
induce remission in MPN patients [116-117]. Further understanding the 
requirements for JAK2-V617F signaling toward cellular transformation may 
uncover additional sites for therapeutic intervention for MPNs. 
 
Cholesterol and MPNs  
 Cholesterol is an essential component of the plasma membrane of 
mammalian cells. Due to its hydrophobic properties, cholesterol contributes to 
creating a barrier between the cellular contents (organelles, cytoplasm, proteins, 
molecules, etc.) and the extracellular environment [118]. Recently, evidence of 
cholesterol playing a role in MPN development in mice came to the forefront. 
Yvan-Charvet and colleagues found that inhibition of cholesterol efflux, through 
knockdown of ATP-binding cassette transporters (ABCA1 and ABCG1) resulted 
in an MPN phenotype in mice, implicating a role for cellular cholesterol in MPN 
formation. Furthermore, this group showed that high density lipoprotein (HDL), a 
molecule that binds cholesterol and promotes its removal from the plasma 
membrane, rescued the MPN phenotype in mice [119], again implicating 
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cholesterol in development of MPNs. HDL also inhibits hematopoietic stem cell 
proliferation, suggesting cholesterol plays a role in regulating blood cell growth 
and development. It remains unknown what role cholesterol plays in MPN 
development. However, since cholesterol functions in the plasma membrane in 
cells it is possible cholesterol-containing lipid rafts are important in this process. 
 
Lipid Rafts 
 Lipid rafts are defined by the enrichment in cholesterol and sphingolipids, 
creating a rigid microdomain within the fluid plasma membrane [120-121]. Lipid 
raft biology has improved our understanding of the plasma membrane, where 
Singer and Nicholson initially proposed the fluid mosaic model to describe a 
plasma membrane. This model describes proteins and molecules moving freely 
and randomly in the fluid-like plasma membrane [122]. We now know there is 
more order to the membrane, and that order largely comes from lipid rafts. These 
tightly packed microdomains arise due to the interaction between the highly 
saturated fatty acid side-chains of sphingolipids and the polar head groups of 
cholesterol. In comparison to the lipids in the fluid portions of the membrane, lipid 
raft sphingolipid acyl chains are generally more saturated, contributing to a 
partition of a tightly packed microdomain within the fluid plasma membrane [120-
121].  
 Key functions attributed to lipid rafts include providing a platform for 
molecular complexes with subsequent effects on signal transduction [121]. This 
signal transduction function can be further divided into two categories, inclusion 
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and exclusion. Firstly, lipid rafts can allow the inclusion of protein or molecules 
into the raft supporting signaling complex formation and molecular interactions. 
Examples of the inclusion function include signaling by EpoR [123], the platelet 
derived growth factor receptor (PDGF-R), and the insulin receptor [121], each of 
which includes the receptor and signaling mediators in lipid rafts. Secondly, lipid 
rafts can exclude proteins or molecules from lipid rafts, thereby sequestering 
components of signaling complexes. Examples of the exclusion function include 
the exclusion of negative regulators from lipid rafts, as in the cases of CD45, a 
negative regulator of JAK/STAT signaling that is excluded from lipid rafts after 
cytokine stimulation [124] and CD22, a negative regulator of B-cell receptor 
(BCR) activation that is excluded from lipid rafts during stimulation of the BCR 
[125]. Tied into the alteration of signal transduction function of lipid rafts, is the 
potential ability of lipid rafts to alter the functions of proteins due to interactions 
with the lipid environment within lipid rafts, whereby depending on the nature of 
the protein and lipid raft interactions, the protein may function differently. This is 
proposed for some RTKs [124]. Some viruses utilize lipid rafts to gain entry into 
cells [126]. Finally lipid trafficking, which aids in the transport of lipids from one 
region of the cell to another, is another function attributed to lipid rafts [120-121, 
126]. 
 There are two types of lipid rafts, caveolar and non-caveolar lipid rafts. Of 
the two types of lipid rafts, caveolae were discovered first, after flask-like 
invaginations were detected in the plasma membrane [127-129]. These 
membrane invaginations where enriched in cholesterol, sphingolipids, and a 
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protein called caveolin-1 (cav-1). Knockout of cav-1 in cell lines shows loss of the 
invaginations in the plasma membrane, suggesting a structural function for cav-1 
[127]. Similar to caveolar lipid rafts, non-caveolar lipid rafts are enriched in 
cholesterol and sphingolipids compared to the fluid phase-plasma membrane. 
Also, these two forms of rafts function in the same manner, alteration of signaling 
transduction through inclusive or exclusive mechanisms, lipid trafficking, etc. 
[120-121]. The key difference between the two types of lipid rafts is the presence 
of cav-1, and the subsequent structural dissimilarities in plasma membrane, i.e. 
invaginations in the membrane. 
The non-caveolar lipid rafts (for the remainder of this report, the term ‘lipid 
rafts’ refers to the non-caveolar lipid rafts) were first discovered when small 
regions of the plasma membrane remained intact after solublization with non-
ionic detergents, hence the name detergent resistant membranes, or DRMs [120-
121, 130]. In fact, it is this property that allows for experimentation and 
assessment of lipid rafts.  Detergent solublization of the cell leads to lipid rafts 
remaining intact, and these non-soluble rafts can subsequently be separated 
from whole cell lysate. These small regions were found to be enriched in 
cholesterol and sphingolipids, with certain proteins being associated within these 
DRMs during a variety of cellular circumstances, such as activation of signal 
transduction [121, 130]. 
 
Lipid Rafts and JAK/STAT Signaling 
 Recent work by McGraw et al. demonstrated that wild-type 
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EpoR/JAK2/STAT5 signaling is dependent on lipid rafts (Figure 5). EPO 
stimulation led to an increase in lipid raft aggregates and subsequent EpoR 
localization within the lipid raft. Disruption of lipid rafts resulted in a 
downregulation of wild-type EpoR/JAK2/STAT5 signaling [123]. While JAK2-
V617F-mediated signaling and transformation requires the expression of a 
cytokine receptor, such as EpoR, the role lipid rafts may play in dysregulated 
signaling by JAK2-V617F has not been investigated. This is a major focus of the 
studies of this dissertation. 
 
Mevalonate Pathway 
 The mevalonate pathway is the key pathway responsible for cholesterol 
and isoprenoid biosynthesis (Figure 6). This pathway is present in most 
eukaryotes, archaea, and some eubacteria [131]. Overall, this pathway has 
important implication in cellular processes such as membrane integrity, protein 
prenylation, precursors for hormone production, protein anchoring, and N-linked 
glycosylation. The pathway begins with the conversion of acetate to acetyl-CoA, 
followed by the combination reaction of acetyl-CoA and acetoacetyl-CoA by 3-
hydroxy-3methyl-glutaryl-CoA (HMG-CoA) synthase to form HMGCo-A. The rate 
limiting enzyme in the pathway, HMG-CoA reductase, catalyzes the conversion 
of HMGCo-A to mevalonate. Further downstream from mevalonate and after a 
series of reactions, is the production of isopentyl 5-diphosphate (IPP), a major 
precursor to downstream isoprenoid products. Subsequently, after radical 
coupling reactions with IPP, is the production of farnesylpyrophosphate (FPP). 
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FPP can also be converted to geranylpyrophosphate (GPP). The pathway 
branches off from the main trunk, where geranylgeranyl diphosphate synthase 
catalyzes the reaction that produces geranylgeranylpyrophosphate (GGPP), 
which gives rise to geranylgeranylation of proteins such as Ras and Rho.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FPP can then be converted to dolichol and ubiquinone products. FPP can also 
be converted to squalene through a series of reactions, which can be modified to 
form cholesterol [131].   
Figure 5: JAK2 signaling and lipid rafts. Without cytokine signaling, 
JAK2/cytokine receptor (e.g. EpoR) complexes are located outside of 
lipid rafts. Upon cytokine stimulation, JAK2/cytokine receptor complex 
localize to lipid rafts and promote JAK2 signaling cascade. 
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The mevalonate pathway is regulated by various mechanisms [131], 
including the cholesterol sensing protein, sterol regulatory element-binding 
protein-1 (SREBP-1) which promotes expression of HMG-CoA reductase when 
cholesterol levels are low. High cholesterol levels promote the exposure of 
Lys248 of HMG-CoA reductase, leading to targeting for proteosomal degradation 
[132]. Negative feedback loop regulation with the mevalonate pathway end 
product, farnesol, has been shown to inhibit HMG-CoA reductase translation. 
Additional regulation is also demonstrated through phosphorylation of Ser872 on 
HMG-CoA reductase by AMP-activated protein kinase, effectively inhibiting 
enzyme activity [133]. Furthermore, cholesterol levels can also be controlled by 
cholesterol efflux and influx mechanisms whereby ATP-binding cassette (ABC) 
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Figure 6: The Mevalonate Pathway. Dashed arrows represent multiple 
reactions. 
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transporters promote cholesterol leaving the cell, while upregulation of low 
density lipoprotein (LDL) receptors promote cholesterol entry into the cell [131]. 
Needless to say, cholesterol and the mevalonate pathway are carefully regulated 
by cells. 
 
Statins 
 Statins are a class of drugs that inhibit HMG-CoA reductase, the rate-
limiting enzyme in cholesterol biosynthesis [134-135]. Statins, since their 
approval by the FDA in 1987, have been given to patients to reduce cholesterol. 
Statins are effective at treating hypercholesterolemia and preventing a state of 
hypercholesterolemia. Statins reduce the morbidity and mortality associated with 
cardiovascular disease [134-135]. Currently, there are seven statins on the 
market, with both synthetic and naturally occurring statins available [134-136].  
These include, among others, simvastatin (Zocor®), atorvastatin (Lipitor®), and 
lovastatin (Mevacor®). All statins inhibit HMG-CoA reductase to variable 
degrees, and function by binding to the enzyme and thus blocking the ability of 
the substrate to enter the active site [137]. Currently, statins are amongst the 
best selling drugs in the world and recently became available in generic form in 
the United States. A recent estimate shows that over eight million people take 
statins and are generally well-tolerated [135, 138].  
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Statins and Cancer 
Statins are the mainstay treatment to prevent and control cardiovascular 
diseases [138]. However, due the large numbers of patients worldwide that take 
statins and the large cohorts involved in the hypercholesteremia clinical trials, the 
effects statins impose on other aspects of health have been analyzed in a 
retrospective fashion. In particular, multiple reports have suggested that statins 
reduce the risk of some forms of cancer including: melanoma, breast, colon, 
prostate [139-142] and uterine cancer [143]. These and other findings promoted 
investigators to more directly test the effects of statins in in vitro and in vivo 
cancer models. Indeed, statins were found to be effective at inducing cytotoxic 
effects in in vitro cancer models including: melanoma [144], glioma [145], 
neuroblastoma [146], and AML cell lines [147]. Mouse models that recapitulated 
a variety of cancers including: ErbB2+ breast cancer [148], melanoma [149], 
prostate cancer [150], colorectal cancer [151], and leukemia [152] demonstrated 
an improvement in survival or tumor regression with statin treatment.   
 
Statins Impact Hallmarks of Cancer 
The mode in which statins elicit anti-tumor effects has been under 
investigation over the past decade. Multiple groups have shown statins promote 
a block in the tumor cell growth in prostate, gastric, AML, pancreatic, colorectal, 
melanoma, neuroblastoma, and mesothelioma cancer cell lines [153-154].These 
anti-tumor effects were in part due to the inhibition on end products of the 
mevalonate pathway, including, inhibition of farnesylpyrophosphate, 
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geranylgeranylpyrophosphate, dolichol, and cholesterol production [153]. 
Additionally, statins were shown to be effective at reducing proliferation induced 
by Ras and Rho activation, whose activities are dependent on prenylation. 
Furthermore, anti-tumor effects induced by statins are also explained by 
stabilizing cell cycle kinase inhibitors, p21 and p27 [155]. In line with blocking 
tumor cell growth, statins also have been shown to induce apoptosis through 
their ability to upregulate pro-apoptotic Bax and Bim proteins, while 
downregulating the anti-apoptotic Bcl-2 protein [153, 156]. Statins have also 
demonstrated the ability to induce the activation of caspases 3, 7, 8, and 9 [157-
159]. 
Statins block metastatic processes by downregulating endothelial 
leukocyte adhesion molecule, E-selectin [160], and matrix metalloproteinase 9 
(MMP 9) expression [161], and block tumor cell invasion induced by epithelial 
growth factor [162]. Consistent with these data, retrospective analysis of patients 
with prostate cancer found that there was a lower incidence of metastatic 
progression in patients taking low dose statins for reasons other than cancer 
therapeutics, than those who did not take statins  [163]. 
Statins can also impinge on another hallmark of cancer, angiogenesis 
[153, 164]. Pro-angiogenic effects have been observed with low dose statin 
treatment of rabbits and thus statins under these conditions facilitate tumor 
growth. These effects are due in part by activating endothelial nitric oxide 
synthase and protein kinase B [165-166]. However, higher doses of statins 
resulted in inhibition of angiogenesis [153, 164]. High dose statin treatment can 
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decrease vascular endothelial growth factor secretion [167]. These data together 
support the concept that statin effects can vary depending on dose. 
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Figure 7: Statins target hallmarks of cancer. Statins block the growth 
capabilities of cancer by stabilizing p21 and p27, while blocking Ras and 
Rho-dependent growth. Statins also can inhibit angiogenesis by decreasing 
VEGF expression and blocking capillary tube formation. Apoptosis is also 
induced by statin treatment through promoting caspase 3, 7, 8, and 9 
activity and inducing pro-apoptotic Bax and Bim. Additionally, statins 
promote apoptosis by downregulating Bcl-2 expression, an anti-apoptotic 
mediator. Statins are able to downregulate MMP9, while promoting epithelial 
growth factor, which contribute to interfering with metastatic processes. 
Proteins, and/or their activity, whose names are depicted in red text are 
negatively regulated by statins while those depicted in blue text are 
positively regulated by statins [153]. 
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Clinical Trials Using Statins in Cancer Patients 
Clinical trials addressing the direct effects of statins on a variety of 
cancers in humans have been established. Clinical trials demonstrated that 
statins have made positive impacts on tumor/cancer progression in humans with 
melanoma, colorectal cancer, breast cancer, uterine cancer, prostate cancer, and 
AML [153-154, 168-171]. A clinical trial testing the ability of pravastatin to 
improve the survival rate in patients with advanced hepatocellular carcinoma 
showed that patients on statins had a survival rate of 18 months, compared to 
control group whose median survival was 9 months [172]. Similarly, a clinical trial 
with non-metastatic rectal cancer showed that combined treatment with statins 
and neoadjuvant chemoradiation, led to 30% of the statin treated patients to have 
a complete response, while only 17% in the control group [173]. In addition, pro-
longed administration of lovastatin in patients with squamous cell carcinoma of 
the head and neck resulted in 23% of the patients having stable disease 
compared to control group [174]. Concordantly, a small case report of a patient 
with acute myeloblastic leukemia showed that lovastatin treatment led to an 
apparent stabilization of the number of blast cells [175]. A recent report has 
further indicated that statins reduced the mortality associated with cancer after 
analyzing the entire Danish population, aged 40 years and up from 1995 to 2007 
[176]. However, statins have been ineffective in clinical trials with some cancers. 
For example, a clinical trial testing simvastatin in chronic lymphocytic leukemia 
patients showed no difference compared to control group [177]. Together these 
data suggest that statins may have therapeutic benefit in some, but not all 
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cancers. Nonetheless, clinical trials testing statins in cancer patients have shown 
some success, supporting further investigation of statin therapy in cancer. 
 
Statins in Combination with Other Agents 
Another key aspect to statin treatment in the setting of cancer is the 
finding that statins have been found to enhance the effects of other established 
chemotherapeutic agents and cytokines [153, 178-179]. For example, lovastatin 
and TNFα together enhanced growth inhibition of melanoma and AML cell lines 
and increased survival of murine melanoma and AML models [178-179]. 
Cisplatin, 5-fluorouracil, and doxorubicin have also demonstrated cooperativity 
when combined with statins in colon cancer, melanoma, and lung cancer cell 
lines [180-183]. Combination treatment of lovastatin and paclitaxel exaggerated 
the apoptosis induction compared to single agent treatment alone in AML cell 
lines [184]. Interestingly, combination treatment in the case of lovastatin and 
doxorubicin, resulted in a reduced risk of doxorubicin-associated cardiotoxicity 
[182, 185], suggesting that statins, aside from inducing anti-cancer effect, may 
work in combination with other therapies to minimize side effects of treatment. 
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Chapter 2 
 JAK2-V617F-mediated signaling is dependent in lipid rafts and statins 
inhibit JAK2-V617F-dependent cell growth 
 
Introduction 
 Somatic mutations in the gene encoding the JAK2 tyrosine kinase are 
prevalent in myeloproliferative neoplasms (MPNs) [66-70, 74], a group of 
hematopoietic stem cell diseases characterized in part by expansion of one or 
more lineages in the myeloid compartment [186]. Classical MPNs include 
polycythemia vera (PV), essential thrombocythemia (ET), and primary 
myelofibrosis (PMF). Patients with PV have a defect in the erythroid lineage, 
leading to overproduction of red blood cells (RBCs). The main cellular defect in 
ET lies within the thrombocytic lineage, resulting in an overproduction of 
platelets. In PMF excessive blood cell formation in the bone marrow results in 
fibrosis of the bone marrow which can impede proper hematopoiesis [186]. A 
recurrent activating mutation in JAK2, JAK2-V617F is found in ~95% of PV 
patients and about 50% of ET and PMF patients [187]. Some JAK2-V617F-
negative MPN patients exhibit other mutations that alter JAK2 signaling. These 
include exon 12 mutations of JAK2, mutations of cytokine receptors that signal 
through JAK2, and mutations of other proteins that regulate JAK2 function.  
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Importantly, many of these mutations can initiate an MPN-like syndrome in 
mouse models [187]. Collectively, these data suggest that JAK2 dysregulation 
contributes to MPN formation. 
 While JAK2 inhibitors have had significant success in recent clinical trials 
due to their ability to reduce constitutional symptoms and thus relieve suffering of 
patients, they have not readily reduced the allele burden and thus do not induce 
remission in patients [94, 114]. Thus, alternative therapeutic approaches that 
enhance neoplastic cell killing are still needed for MPN patients. Further 
understanding the regulation of JAK2 signaling in MPN cells may uncover 
additional sites of potential therapeutic intervention that may be effective at 
treating MPNs.       
 JAK2 normally functions in signal transduction initiated by cytokine 
receptor activation. JAK2 associates with cytokine receptors and becomes 
activated following cytokine receptor stimulation by ligand [39]. Cytokine binding 
to its receptor causes a conformational change in receptor-associated JAK2 
proteins, which then trans-phosphorylate each other leading to their full activation 
[73]. Activated JAKs then phosphorylate the cytokine receptor, creating binding 
sites for downstream mediators like signal transducer and activator of 
transcription (STAT) molecules. STATs are then phosphorylated on tyrosines by 
activated JAKs [39]. Phosphorylated STATs function as transcription factors, 
promoting expression of genes involved in growth, survival, differentiation, etc. In 
the case of JAK2-V617F, the phenylalanine to valine substitution at amino acid 
residue 617, allows for dysregulated kinase activity through loss of an 
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autoregulatory function of the pseudokinase domain [188]. This mutation 
effectively leaves JAK2 primed for activation by circumventing the need for a 
conformational change of the kinase induced by cytokine receptor stimulation.  
However, even though JAK2-V617F does not require cytokine stimulation to be 
activated, a cytokine receptor is still necessary for JAK2-V617F-mediated 
signaling and cell transformation [73, 189]. Thus, it is thought that cytokine 
receptors provide a scaffolding function for JAK2-V617F-initiated signaling. 
 Erythropoietin receptor (EpoR) uses JAK2 to transduce signals initiated by 
erythropoietin (Epo) to promote RBC production [190]. We have recently shown 
that wild-type EpoR/JAK2 signaling requires lipid rafts [123]. Lipid rafts are 
microdomains of the plasma membrane that are enriched in cholesterol and 
sphingolipids [191]. These microdomains are more rigid than the majority of the 
plasma membrane and have been shown to function in membrane trafficking, 
cytoskeletal arrangement [120], virus entry [192-193], and cellular signaling 
[121]. Protein compartmentalization in membrane rafts facilitates protein 
interactions that regulate signal transduction activation, especially for some 
receptor-initiated signals at the cell surface [121].  
While we have shown that wildtype EpoR/JAK2 signaling requires 
membrane rafts for proper signaling [123], the role of cholesterol and membrane 
rafts in pathologic signaling by JAK2-V617F in MPNs has never been reported, 
and this is what we explored in this study. We show for the first time that JAK2-
V617F is localized to lipid rafts and JAK2-V617F-dependent signaling requires 
membrane cholesterol. By utilizing JAK2-V617F-dependent MPN model cell lines 
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as well as primary cells from JAK2-V617F-positive MPN patients, we also show 
that JAK2-V617F-mediated transformation is sensitive to statins, inhibitors of the 
cholesterol-producing mevalonate pathway. Our data showing the requirement of 
cholesterol for JAK2-V617F-mediated signaling and the sensitivity of MPN cells 
to statins suggests that statins could potentially be incorporated into a 
therapeutic strategy for MPNs.  
 
Results 
JAK2-V617F co-localizes with lipid rafts 
 HEL and SET-2 cells are widely used as MPN model cell lines to study 
JAK2-V617F-mediated transformation in MPNs. Each of these patient-derived 
cell lines expresses endogenous JAK2-V617F and requires this activated JAK2 
for growth [194-195]. We first assessed if JAK2-V617F co-localized with lipid 
rafts in cells by utilizing immunofluorescence. We stained HEL cells, which are 
homozygous for JAK2-V617F [196], for GM1 ganglioside (red fluorescence), a 
lipid raft-associating lipid and JAK2 (green fluorescence) and used single z plane 
images from confocal microscopy to visualize localization. Yellow in HEL cell 
images represent green and red fluorescence overlap, suggesting JAK2 co-
localization with lipid rafts (Figure 8A). The lipid raft disrupting agent methyl-beta 
cyclodextrin (MBCD) acts by binding to cholesterol and removing it from the 
membrane [197]. When HEL cells were treated with MBCD and stained for JAK2 
and lipid rafts, single z plane images from confocal microscopy showed 
disruption of red staining, indicative of lipid raft disruption and thus confirming our 
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raft staining (Figure 8A). To reduce the possibility of false-positive staining, we 
used a second JAK2 antibody and obtained similar results (Figure 8B). To 
ensure the antibodies used in staining JAK2 in Figure 1A and 1B were specific 
for JAK2, we immunoblotted HEL cell lysates with the same JAK2 antibodies 
(Cell Signaling Technology, Inc. used in Figure 1A and Imgenex, Corp. in Figure 
8B). Only a single band at the expected molecular weight for JAK2 (~125 kDa) 
was detected, demonstrating the JAK2 specificity of the antibodies (Figure 8C). 
These same two JAK2 antibodies were also used in a recent study that utilized 
immunofluorescence to study JAK2 sub-cellular localization in MPN cells [38].  
We next employed a second method to detect the presence of JAK2-
V617F protein in lipid rafts. Lipid rafts are resistant to Triton X-100 solubilization 
and are referred to as detergent resistant membranes (DRMs) because of these 
properties. They can be isolated by ultra-centrifugation based on their differential 
buoyant density compared to other membranes and cellular constituents [121]. 
We utilized an iodixanol gradient to isolate DRMs from Triton X-100 solubilized 
SET-2 whole cell lysate. After centrifugation, fractions were removed from the top 
of the gradient, resulting in lower density fractions being present in the lower 
numbered fractions. Equal volumes of each fraction were analyzed by dot blot 
analysis to identify the fractions containing the resident raft lipid marker GM1 
ganglioside (Figure 9A). GM1 was detected predominantly in fraction 2, as well 
as in fractions 3, 5, and 6. Separation of GM1 between fractions 3 (lower buoyant 
density) and 5 (higher buoyant density) suggests that DRMs separated from the 
whole cell lysate (fractions 5 and 6), and identifies the lower buoyant 
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Figure 8: Mutant JAK2 co-localizes with lipid rafts in JAK2-V617F-
positive cells. (A) HEL cells, untreated (left) or treated with MBCD (10 mM, 
30 min, right), were stained with antibodies that recognize JAK2 (Cell 
Signaling Technology, CS) (green) and lipid rafts were detected by CTB, 
which binds to lipid raft lipid, GM1 ganglioside (red). Co-localization is 
demonstrated by merging green and red images, creating yellow. 4’ 6-
diamidino-2-phenylindole (DAPI) was used to stain the nucleus (blue). Cells 
were analyzed by confocal microscopy and single z plane images are 
shown. (B) The experiment in (A) was repeated using a second JAK2 
antibody (Imgenex, IMG). (C) Immunoblot analyses showing total JAK2 
expression in HEL cells using two different antibodies, CS (left blot) versus 
IMG (right) blot, used in (A) and (B), respectively, are shown. Molecular 
weights are indicated in kDa. Immunoblots demonstrate specificity to JAK2 
(c. 125 kDa).  
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density fractions as raft-containing fractions (fractions 2 and 3) (Figure 9A). We 
then analyzed each fraction by immunoblotting for JAK2.  Although the majority 
of JAK2 was present in the lower/cell lysate fraction (fraction 6), JAK2 was 
detectable in the raft fraction (fraction 2) in the untreated SET-2 cells (Figure 9B). 
A resident raft protein, Flotillin-1 was primarily detected in fraction 2, supporting 
our raft fraction designation. However, when SET-2 cells were treated with 
MBCD, JAK2 was no longer found in the lower buoyant density fraction 2, but 
solely in the higher buoyant density non-raft fractions (higher numbered 
fractions), suggesting that raft disruption by MBCD altered JAK2 protein 
localization (Figure 9C). MBCD treatment also shifted the raft marker Flotillin-1 
from raft fractions to higher density buoyant fractions (higher fraction numbers), 
demonstrating effective disruption of lipid rafts (Figure 2C). Based on our 
immunofluorescence and DRM isolation data, we conclude that JAK2-V617F can 
be detected in lipid rafts, and the lipid raft-disrupting agent, MBCD, can abrogate 
this sub-cellular localization.  
 
Lipid raft disrupting agents downregulate JAK2/STAT5 activation in JAK2-V617F-
dependent cell lines 
Because JAK2-V617F localization in lipid rafts was abrogated by the raft-
disrupting agent, MBCD, we next investigated the effect lipid raft disrupting 
agents had on signaling induced by JAK2-V617F. To test this we treated the 
JAK2-V617F-dependent patient-derived cell lines HEL, SET-2, and Uke1 with 
lipid raft disrupting agents, which function by affecting membrane cholesterol. 
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These cell lines express JAK2-V617F and JAK2 signaling, including STAT5 
activation, is dependent on JAK2-V617F [194]. MBCD treatment of HEL cells 
Figure 9: JAK2 is present in fractions containing detergent 
resistant membranes. (A) SET-2 cell lysates were analyzed by 
density buoyant gradient fractionation. Fractions were removed 
from the top of the gradient and thus lower fraction numbers 
correspond to lower buoyant density fractions. Each fraction 
was analyzed by dot blot for GM1 ganglioside, a resident raft 
lipid, using CTB as a probe. Separation of GM1into lower and 
higher buoyant density fractions suggests separation of DRMs. 
Highest detection of GM1 is present in fraction 2, thus 
designating fraction 2 as the raft fraction. (B) Immunoblot 
analyses of gradient fractions of untreated cells to detect JAK2 
or the resident lipid raft marker, Flotillin-1. (C) Immunoblot 
analyses for JAK2 and Flotillin-1 as in (B), but utilizing MBCD-
treated SET-2 cells. MBCD re-distributed JAK2 and Flotillin-1 to 
the higher density non-raft fractions. Molecular weights are 
indicated in kDa.  
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decreased P-JAK2 as shown by immunoblotting for P-JAK2 in total cell lysates 
(Figure 10A) and in JAK2 immunoprecipitations (Figure 10A, right panel). 
Activation/phosphorylation of STAT5 was effectively eliminated by MBCD 
treatment. Additionally, MBCD treatment resulted in a marginal decrease in P-
Akt, another downstream effector of JAK2-V617F activity, in HEL cells (Figure 
10A). Similar results were seen in SET-2 cells where MBCD treatment 
significantly decreased P-JAK2, P-STAT5, and P-Akt (Figure 10A).  Likewise, 
MBCD treatment decreased P-STAT5 and P-AKT levels in Uke1 cells (Figure 
10A). To test the effect of lipid raft disruption in a non-JAK2-V617F transformed 
myeloid cell line, we treated K562 cells, which display constitutive JAK2/STAT5 
signaling due to the activated BCR-ABL tyrosine kinase, with MBCD. MBCD 
treatment did not significantly affect activation of JAK2 or STAT5 in K562 cells 
(Figure 10B), 
Filipin complex is a lipid raft disrupting agent that functions through a 
different mechanism than MBCD. While MBCD removes cholesterol from the 
membrane, filipin complex binds to cholesterol in the membrane thereby 
interfering with proper lipid raft integrity [198]. Filipin complex is a weaker lipid 
raft disruptor than MBCD [199-200]. Filipin complex treatment of HEL cells also 
led to a decrease in JAK2/STAT5 activation, with a modest effect on P-JAK2 but 
a significant reduction of P-STAT5 (Figure 10C).  
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Statins inhibit growth and viability of JAK2-V617F-dependent cells 
 
P-JAK2
JAK2
P-STAT5
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P-JAK2
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Figure 10: Lipid raft disrupting agents downregulate signaling in 
JAK2-V617F-dependent MPN model cell lines. (A) The JAK2-V617F-
dependent cell lines HEL, SET-2, and Uke1 were left untreated (-) or 
treated with MBCD (10 mM) for 30 minutes (+). Lysates were analyzed by 
immunoblotting with antibodies that recognize phosphorylated/activated (P-
) JAK2, STAT5, and Akt, as well as total JAK2, STAT5, and Akt, as 
indicated. Arrow indicates mobility of JAk2 (125 kDa) in SET-2 cells. (B) 
K562 cells, a BCR-ABL-positive CML cell line that has wild-type JAK2, but 
constitutive JAK2/STAT5 activation, were left untreated (-) or were treated 
with MBCD (+) as in (A) and analyzed by immunoblotting with antibodies 
that recognize P-JAK2, JAK2, P-STAT5, and STAT5, as indicated. (C) HEL 
cells were left untreated (-) or were treated filipin complex (1 µg/mL) for 15 
minutes (+). Lysates were analyzed by immunoblotting with antibodies that 
recognize P-JAK2, JAK2, P-STAT5, and STAT5, as indicated. 
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HEL, SET-2, and Uke1 cells require JAK2-V617F signaling for growth 
[194-195] and our data indicates lipid raft disruption has a negative effect on 
JAK2-V617F-dependent signaling (Figure 10). We next wanted to disrupt  
JAK2-V617F localization in lipid rafts in a longer term of study in order to analyze 
effects on growth and survival of these JAK2-V617F-dependent cells.Statins 
inhibit the rate-limiting enzyme, HMG-CoA reductase, in the mevalonate pathway 
which leads to cholesterol biosynthesis [201] and can also be used to alter 
cholesterol-rich lipid rafts [202]. In addition, statins have been shown to alter the 
localization of cytokine receptors (e.g. EpoR) to the plasma membrane, which 
could also affect JAK2-dependent signaling in lipid rafts [203]. Simvastatin 
treatment of HEL cells, as well as SET-2 cells, led to a dose-dependent reduction 
in total viable cell numbers over time (Figure 11A). Similar results were seen with 
lovastatin and atorvastatin (data not shown). Simvastatin treatment reduced the 
viability of HEL cells, while the viability of K562 cells was not significantly affected 
(Figure 11B). Since we utilized statins to target cholesterol, we wanted to confirm 
cholesterol levels were indeed affected. We determined that the low dose of 
simvastatin we utilized in this study did indeed decrease cholesterol levels in 
HEL cells (Figure 11C), with 5 µM simvastatin reducing cellular cholesterol by 
~34% after four days of treatment. Similarly, cholesterol reduction was observed 
with lovastatin and atorvastatin treatment (not shown). Finally, statin treatment 
inhibited the localization of JAK2-V617F to lipid rafts as determined by  
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Figure 11: Simvastatin reduces JAK2-V617F-dependent cell viability and 
growth. (A) HEL (left graph) or SET-2 (right graph) cells were treated with 0 
(0.1% dimethyl sulfoxide, DMSO) to 10 µM simvastatin (Sim). Trypan blue 
exclusion was used to enumerate total viable cells over time. (B) Percent 
viability of HEL (left graph) and K562 (right graph) cells was determined by 
trypan blue exclusion over time following either DMSO or 5 µM simvastatin 
(Sim) treatment. Data shown is representative of three independent 
experiments. (C) Cholesterol was measured in HEL cells after 4 d of 0 
(DMSO), 1 µM, or 5 µM simvastatin treatment. Error bars indicate standard 
deviation and p value was determined by T-test (GraphPad Software, Inc.) 
This experiment is representative of three independent experiments. (D) Co-
localization of JAK2-V617F and lipid rafts in HEL and SET-2 cells was 
performed as in Figure 1A and the Pearson’s correlation analysis for co-
localization was determined using Definiens Developer software. Data 
represents the average (with standard deviation) correlation coefficient for 
four to five images for each condition for each cell line. 
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immunofluorescence (Figure 11D), however it did not disrupt lipid raft formation 
(data not shown).   
 
Simvastatin induces apoptosis and downregulates JAK2/STAT5 activation in 
JAK2-V617F-dependent cell lines 
Since we observed a decrease in cell viability with statin treatment, we 
next assessed if statins could induce apoptosis of JAK2-V617F-dependent cell 
lines.  Simvastatin treatment (5 µM) induced apoptosis of HEL cells as measured 
by annexin V staining (Figure 12A). PARP cleavage after simvastatin treatment 
of HEL cells for 24 and 48 hours also demonstrated simvastatin induced 
apoptosis in a dose and time-dependent manner, even at the very low dose of 1 
µM (Figure 12B). Induction of PARP cleavage was also seen in SET-2 cells 
treated with simvastatin (Figure 12B). Simvastatin treatment of HEL cells 
reduced the activated/phosphorylated levels of JAK2 and to a less significant 
extent STAT5 (Figure 12C). Similar results were seen in SET-2 cells (Figure 
12C). However, JAK2/STAT5 activation in K562 cells was less sensitive to 
simvastatin treatment than in JAK2-V617F-dependent cells (Figure 12C).  
 
Simvastatin inhibits Primary MPN Cell Growth 
Hematopoietic progenitor cells from MPN patients form erythroid colonies 
in methylcellulose medium lacking erythropoietin (Epo) [204]. To test the effects 
of statin treatment on primary MPN cells we performed colony formation assay 
using mononuclear cells (MNCs) from peripheral blood of two JAK2-V617F- 
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Figure 12: Simvastatin induces apoptosis and downregulates 
JAK2/STAT5 activation in JAK2-V617F-dependent cells. (A) HEL cells 
were treated 0 (DMSO), 1 µM, and 5 µM simvastatin for 24 and 48 hours and 
stained with Annexin V and analyzed by flow cytometry to detect Annexin V-
positive cells. Error bars indicate standard deviation of triplicate samples. This 
experiment was performed four times with similar results. (B) Immunoblot 
analysis to detect PARP cleavage after 0 (DMSO), 1 µM, and 5 µM 
simvastatin treatment of HEL cells (top blot) and SET-2 cells (bottom blot) for 
24 and 48 hours. (C) HEL, SET-2, and K562 cells were treated with 5 µM 
simvastatin for 4 d and cellular lysates were analyzed by immunoblotting for 
P-JAK2, JAK2, P-STAT5, STAT5, and Hsp90 (as additional loading control), 
as indicated. 
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positive MPN patients. Thus, JAK2-V617F-positive erythroid progenitors will 
proliferate and differentiate to form erythroid colonies in the absence of Epo. 
Simvastatin reduced Epo-independent erthyroid colony formation of cells from 
three independent MPN patients tested (Figure 13A). These patients included a 
JAK2-V617F-positive PV patient (MPN 1), a JAK2-V617F-positive MF patient 
(MPN 2), and a JAK2-V617F-positive post-PV/MF patient (MPN 3). Inhibition of 
colony formation was seen with 5 µM simvastatin.  We utilized simvastatin at 2.5 
µM in the experiment with MPN 3 and this lower dose inhibited colony formation 
to a similar extent (~75%).  Similar experiments performed with cells from normal 
healthy controls (n=4) suggested erythroid colony formation from normal 
progenitor cells is unaffected by statin treatment at the same dose that shows 
efficacy at reducing colony formation of cells from MPN patients (Figure 13B).  
 
Discussion 
JAK inhibitor therapy was recently approved for the treatment of MF 
patients. JAK inhibitors have proven to be effective at improving constitutional 
symptoms and reducing spleen size in MPN patients. However, they do not 
appreciably decrease disease allele burden and thus do not induce remission in 
patients [94, 205]. JAK inhibitors can block the aberrant JAK2 and JAK1 
signaling induced by the cytokine storm associated with MPNs, and this may be 
the basis for improvement in MPN patients’ constitutional symptoms [94, 205]. 
With the inability of JAK inhibitors to decrease the allele burden in MPN patients, 
exploration of alternative therapeutic approaches for MPN patients continues. We 
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Figure 13: Simvastatin reduces erythroid colony formation of 
primary MPN cells. (A) Colony formation assay performed using 
mononuclear cells (MNCs) isolated from peripheral blood of MPN 
patients (n = 3). MNCs were plated in cytokine containing 
methylcellulose medium without Epo and Epo-independent erythroid 
colonies [as erythroid burst-forming units (BFU-Es)] were enumerated 
after 12 d of incubation. The experiment performed with either 0 
(DMSO), 2.5 µM, or 5 µM simvastatin (Sim), as indicated. Data is 
presented as number of BFU-Es per 105 cells plated. MPN patients 1, 2, 
and 3 are a JAK2-V617F-positive PV patient, a JAK2-V617F-positive MF 
patient, and a JAK2-V617F-positive post-PV/MF patient, respectively. 
(B) The same experiment was performed with cells from healthy controls 
(n = 4) and with erythropoietin in the medium. All error bars represent 
the standard deviation of replicate plates. 
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initiated our studies to further our understanding of the requirements for JAK2-
V617F-mediated signal transduction in an effort to uncover novel avenues for  
 therapeutic intervention for MPNs. We recently demonstrated that EpoR/JAK2 
signaling requires lipid raft formation [123] and thus wanted to determine the 
potential role of lipid rafts in deregulated JAK2 signaling in MPNs. While previous 
studies support the notion that JAK2 functions in lipid rafts [123, 206], our studies 
are the first to demonstrate that the MPN driver JAK2-V617F co-localizes with 
lipid rafts (Figures 1 and 2). Localization of this tyrosine kinase to lipid rafts is not 
seen in all cells, largely because not all cells exhibit raft staining (Figure 1). This 
may be due to the dynamic nature of lipid rafts, which is influenced by factors 
such as variability in raft size and half-life [207-211]. In addition, only a minor 
fraction of JAK2 was associated with DRMs. This is not surprising for multiple 
reasons. First, rafts are dynamic in nature and all cells did not display raft 
staining. Second, JAK2 is a cytoplasmic protein and more recently has been 
found in the nucleus of cells, including MPN cells [38, 212]. Third, our hypothesis 
is that JAK2-V617F is associated with a transmembrane receptor, such as a 
cytokine receptor (e.g. EpoR). Therefore, JAK2-V617F is not physically present 
in rafts per se, but rather associated with a protein in rafts.  DRM isolation 
experiments utilize an overnight ultracentrifigation spin and it is likely that some 
JAK2 protein would not maintain its interaction with raft-associated proteins 
during this protocol and thus fractionate with the remainder of the JAK2, which is 
non-raft associated. 
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 Using agents that disrupt cholesterol in the plasma membrane, we found 
that JAK2 and STAT5 activation in JAK2-V617F-dependent cells were dependent 
on cholesterol in the plasma membrane, while JAK2 and STAT5 activation in 
K562 cells, which express wildtype JAK2, were not (Figure 3). JAK2-V617F 
requires cytokine receptors for activation [73, 189] while wildtype JAK2 activation 
in K562 cells is likely induced by the BCR-ABL tyrosine kinase [213-214]. We 
believe that JAK2 activation by mechanisms that involve a cell surface receptor 
may be more sensitive to lipid raft disruption than activation of JAK2 by non-
receptor mechanisms, such as BCR-ABL. The BCR-ABL induced constitutive 
JAK/STAT signaling may not rely on lipid rafts because the cytoplasmic BCR-
ABL tyrosine kinase may activate or signal to these molecules directly [213-214]. 
Lipid rafts may play an integral role in the receptor scaffolding function for JAK2-
V617F activation by coordinating the proper molecular complexes at the cell 
surface [73, 121, 189].   
MPN model cell lines are also more sensitive to statin treatment than 
BCR-ABL positive K562 cells. We find MPN cells are sensitive to single digit 
micromolar statins, which is similar to certain AML cell lines, but significantly less 
than cells from a variety of solid tumors [215]. This may, in part, be due to the 
inherent driving oncogenic lesions in these cells, compared to other cancers. 
Statin treatment also inhibited the growth of primary MPN cells. Importantly, the 
growth of primary MPN cells is more sensitive to statins than cells from healthy 
controls (Figure 6). This is in agreement with other studies looking at the effect of 
statins on normal and neoplastic hematopoietic cell growth, where normal 
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hematopoietic cells are not sensitive to statins until high doses are achieved 
[215-217]. This suggests statins may be considered as a potential therapeutic 
agent for MPNs, although the effect of statins on JAK2-V617F-negative MPNs 
needs to be determined.  
Although a requirement for lipid rafts in JAK2 signaling could provide a 
mechanistic rationale for the use of statins to inhibit MPN cells, cholesterol is not 
the only end product of the mevalonate pathway [169]. While we have not 
obtained evidence that statins inhibit lipid raft formation in our cell systems, we 
show that statins do appear to inhibit the localization of JAK2-V617F to lipid rafts 
(Figure 4D), which in effect also targets the requirement of rafts for signaling. 
Importantly, statins also inhibit protein prenylation by inhibiting the production of 
farnesyl pyrophosphate and geranygeranyl pyrophosphate, two other end 
products of the mevalonate pathway downstream of HMG-CoA reductase. 
Interestingly, it has been shown that EpoR cell surface expression requires 
protein geranylgeranylation [203]. It is possible that the effects of statins in MPN 
cells may be mediated through protein prenylation, perhaps through inhibition of 
a requisite cytokine receptor for JAK2-V617F-mediated signaling. In our efforts to 
ascertain further details regarding the mechanism of statin affects on MPN cells, 
we have determined that adding back geranylgeranyl pyrophosphate to cells can 
reduce the statin-induced loss of viability of cells, but does not significantly 
restore proliferation of cells (not shown). Thus, while the mechanistic details by 
which statins inhibit MPN cell growth are likely complex and remain to be 
elucidated, our data suggest that statins may be a candidate to be used as a 
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potential therapeutic strategy to target MPN cells. While these details will be the 
focus of future studies, it is important to note that statins induce MPN cell 
apoptosis (Figure 5A and B). This is significant since JAK2 inhibitors fail to 
decrease allele burden in patients, additional therapeutic approaches to 
complement JAK2 inhibitors are needed, especially ones that can contribute to 
an apoptotic response in MPN cells. 
While our work is the first to directly investigate the role of lipid rafts and 
cholesterol in MPN cells, there is additional evidence that suggests cellular 
cholesterol levels could play a role in MPN cell biology. Mice deficient in 
cholesterol efflux transporters ABCA1 and ABCG1 display an MPN-like 
phenotype [119]. This suggests that an increase in cellular cholesterol in 
hematopoietic cells can lead to an MPN-like phenotype. In fact, Yvan-Charvet et 
al. [119] demonstrated that hematopoietic stem and progenitor cells from these 
mice displayed aberrant proliferation, and that removal of cholesterol from these 
cells restored a normal proliferative phenotype. These studies clearly indicate 
that cellular cholesterol can regulate growth control pathways of hematopoietic 
stem and progenitor cells, and that increasing cholesterol levels can lead to 
aberrant myeloproliferation. Thus, cellular cholesterol may play an important role 
in the development of human MPNs. Our work showing that alteration of 
membrane cholesterol with lipid raft disrupting agents inhibits JAK2-V617F 
signaling, together with Yvan-Charvet et al [119], suggests that altering 
cholesterol in hematopoietic stem and progenitor cells may affect cell signaling 
that leads to JAK2-V617F-driven myelopoiesis. Thus, altering cellular cholesterol 
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or inhibiting localization of JAK2-V617F to lipid rafts, perhaps through the use of 
statins, may be an effective approach to target the aberrant myelopoiesis 
associated with MPNs. 
The use of statins to treat MPN patients has been previously rationally 
suggested [218-219]. This hypothesis is based on the antithrombotic, 
antiproliferative, proapoptotic, and antiangiogenic effects of statins and the role 
thrombohaemorrhagic complications play in MPNs. The use of statins in the 
treatment of MPNs has been discussed in the context of the potential role of 
chronic inflammation in the development of MPNs. The anti-inflammatory effects 
of statins may be advantageous to MPN patients as chronic inflammation may be 
a driving force toward clonal evolution as well as a deadly myelofibrotic state 
[218-219]. For example, TNFα may contribute to clonal expansion of MPN cells 
[220] and simvastatin lowers TNFα expression in myeloid cells in patients [221]. 
Also, MPN patients have an increased risk of developing both hematologic and 
non-hematologic secondary cancers and this may be due to the elevated 
inflammation associated with MPNs [91, 222]. Thus, in addition to potential direct 
effects of statins on MPN cells, statins may also contribute to the amelioration of 
disease through their anti-inflammatory effects.    
In summary, we find that JAK2-V617F is associated with lipid rafts and 
that signaling by this constitutively activated kinase is dependent on proper lipid 
raft formation. Statins reduce JAK2 localization to lipid rafts, induce apoptosis of 
MPN cells, and inhibit colony formation of primary cells from MPN patients. Since 
JAK inhibitors have not had success at reducing allele burden in MPN patients, 
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additional therapeutic approaches are needed in order to induce remission in 
these patients.  Our work suggests that statins might be an effective component 
of a therapeutic strategy for MPN patients. Additional studies are needed to 
investigate the potential efficacy of statins, alone and in combination with JAK 
inhibitors, as a potential therapeutic option for MPNs. 
 
Materials and Methods  
Immunofluorescence studies 
HEL cells were treated with 10 mM MBCD (Sigma-Aldrich) for 30 minutes 
at 37ºC and 5% CO2. Cells (2 X 106) were washed with chilled RPMI 
supplemented with 10% FBS, followed by a 10 minute incubation with 1 ug/mL 
cholera toxin B (CTB)-conjugate (Vybrant Lipid Raft Labeling Kit, Life 
Technologies) in chilled RPMI/10% FBS for 10 minutes at 4ºC. Cells were 
washed three times with chilled PBS. For experiments in which Imgenex JAK2 
antibody was utilized, anti-CTB antibody (Vybrant Alexa Fluor 594 Lipid Raft 
Labeling kit, component B) was then performed for 10 minutes at 4ºC. Cells (2.5-
5 X 104) were cytospun onto glass microscopes slides. Cells were then fixed 
using Cytofix Fixation Buffer (BD Biosciences) for 10 minutes at 37º C and 
washed with RT PBS. Cells were then permeabilized for 5 minutes using 2 drops 
of 0.5% Triton X-100 in PBS. Slides were washed using RT PBS and 
subsequently blocked with 2% BSA in PBS for 30 minutes at RT and washed 
with RT PBS. Primary antibody incubation followed, using a 1:200 dilution (in 2% 
BSA/PBS) for JAK2 (D2E12, Cell Signaling) or (IMG-3007, Imgenex, Corp.) 
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overnight (o/n) at 4º C. Slides were washed with RT PBS. Secondary antibody for 
JAK2 ensued using Alexa Fluor 488 goat-anti-rabbit (Invitrogen, #411008) at 
1:500 dilution (in 2% BSA/PBS) for 1 hour at RT for the JAK2 (Cell Signaling) 
primary, or DyLight 488 Conjugate donkey-anti goat secondary antibody (705-
486147, Jackson Immunoresearch Laboratories) at a 1:500 dilution for JAK2 
(Imgenex, Corp.) primary. Slides were washed with RT PBS. Mounting media 
(ProLong Gold antifade reagent with DAPI, Invitrogen) was added to each slide 
and covered with a cover slip. Confocal microscopy with a Leica TCS SP5 AOBS 
laser scanning confocal microscope (Leica Microsystems, Germany) was used to 
image cells as previously described [123].  Definiens Developer version 1.5 
(Definiens AG, Munich, Germany) was used to perform Pearson’s Correlation 
analysis for colocalization between lipid raft and JAK2 staining on an average of 
102 cells per image of four or five images per sample.  Briefly, the software was 
used to first segment lipid raft staining areas within each cell and then perform 
the colocalization analysis on each pixel within these areas.  
 
Detergent resistant membrane (DRM) isolation 
SET-2 cells (12.5 X 106) were washed 3X with chilled PBS and lysed in 
250 uL of 0.75% Triton X-100 in TNE (25 mM Tris pH 7, 150 mM EDTA, 1 mM 
DTT, 150 mM NaCl) plus protease and phosphatase inhibitors (1 mM sodium 
vanadate, 10 ug/mL leupeptin, 2 mM sodium pyrophosphate, 2 ug/mL aprotinin, 
1 mM phenylmethylsulfonyl fluoride) and incubated on ice for 5 minutes. Cell 
lysate was sonicated three times for 10 seconds each (FS60 Fisher Scientific 
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Sonicator, Thermo Scientific). Two hundred uL of lysate was added to 400 uL of 
60% OptiPrep™ (Sigma-Aldrich) in TNE buffer, and this mixture was loaded into 
ultra clear ultracentrifuge tubes. Lower density OptiPrep™ solutions were loaded 
on top of 40% layer in decreasing order, 35%, 30%, 25%, 20% and 0%, final 
volume of 600 uL per layer. Samples were spun at 20,000 X g for 20 hours at 
4ºC (Beckman Coulter Optima L-90K ultracentrifuge). Fractions (600 uL) were 
then removed from top to bottom of each gradient. 
 
GM1 dot blots 
Aliquots (5 uL) of each gradient fraction were dotted on nitrocellulose 
membrane, allowed to dry, and the membrane was washed with PBS. 
Membranes were blocked in 5% non-fat dry milk/PBS for 30 minutes at RT. GM1 
detection in dot blots was performed using horse radish peroxidase conjugated 
cholera toxin-B (CTB) (Sigma-Aldrich, C3741) at a 1:10,000 dilution in 5% non-
fat dry milk/PBS, and incubated o/n at 4ºC. Dot blots were washed 3X with 0.3% 
Tween-20/PBS and developed with ECL Plus (Thermo Scientific). 
 
Immunoblotting 
For DRM experiments, 50 uL of fractions were analyzed by SDS-
polyacrylamide gel (SDS-PAGE). For signaling studies, 2-5 X 106 cells were 
washed with chilled PBS and lysed in lysis buffer (25 mM Tris, pH 7.4, 150 mM 
NaCl, 25 mM NaF, 1% Triton X-100, plus protease and phosphatase inhibitors). 
Lysed cells were centrifuged at 14,500 X g for 5 minutes at 4ºC. Protein 
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concentration was determined using Pierce BCA reagent (Thermo Scientific) and 
lysates run on SDS-PAGE. Primary antibodies utilized for immunoblotting 
include: JAK2 (Cell Signaling, #3230), phospho- (P-) JAK2 (pY-1007/1008; Santa 
Cruz, sc-16566), P-STAT5 (pY694; BD Transduction, #611964), STAT5 (Santa 
Cruz, sc-835), Hsp90 (Santa Cruz, sc-7947), P-ERK (pT202/Y204; Cell 
Signaling, #4370), ERK (Santa Cruz, sc-93), P-AKT (pS473; Cell Signaling, 
#4060), AKT (Santa Cruz, sc-8312), and Flotillin-1 (Cell Signaling, #3253). 
Secondary antibodies were from Thermo Scientific.  Immunoprecipitation 
experiments were done using JAK2 antibodies (Cell Signaling, #3230) and 
Protein-A agarose (Thermo Scientific). All blots were developed using West Pico 
Chemilluminescence, ECL Plus, or Super Signal West Femto 
Chemilluminescence (Thermo Scientific). 
 
Cell growth curves 
HEL or SET-2 cells were plated at 0.15 or 0.2 X 106 cells/mL and treated 
with DMSO or simvastatin (Sigma-Aldrich, #S6196). DMSO content was kept 
constant at 0.1% for all samples. Total cells and viability were determined by 
trypan blue exclusion.  
 
Annexin V staining 
HEL cells (1 X 106) were treated with 1 or 5 uM simvastatin for 24 and 48 
hours. Cells were washed with PBS and resuspended in 100 uL 5% BSA in PBS. 
Fifty uL of cells were added to 50 uL 2X Annexin V Binding Buffer (BD 
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Pharmingen) and 11 uL staining solution (8 uL of 10ug/mL propidium iodide (BD 
Pharmingen) plus 3 uL Annexin V-FITC (BD Pharmingen). Cells and staining 
solution were incubated for 15 minutes at RT, followed by addition of 300 uL of 
1X Annexin V Binding Buffer. Samples were analyzed by flow cytometry. 
 
Cholesterol measurement 
Cells (2 X 106) were treated with 1 or 5 uM simvastatin for 96 hours. Non-
viable cells were removed by ficoll centrifugation. Cholesterol was measured 
using Amplex Red Cholesterol Assay kit (Life Technologies), per manufacturer’s 
directions. Fluorescence was measured on a Synergy HT fluorometer (Biotech 
Instruments, Inc) using 560/590 excitation/emission settings. 
 
Colony formation assay 
Peripheral blood mononuclear cells (MNCs) were isolated by ficoll 
separation. Cells (0.5 - 1 X 105) were then plated in methylcellulose containing 
rhSCF, rhIL-3, and rhGM-CSF (Stem Cell Technologies, #H4534), with DMSO 
(0.1%) or 5 uM simvastatin.  For healthy controls, Epo was included at 3 U/mL.  
Cells were incubated for 12 days at 37º C with 5% CO2. Burst-forming erythroid 
(BFU-E) colonies were enumerated. All patients samples were obtained and 
utilized under informed consent through a Moffitt Cancer Center Scientific 
Review Committee approved protocol.  
 
 
 
  
59 
 
 
 
 
 
 
 
 
 
Chapter 3 
 Analysis of the Mechanism of Action of Statins in JAK2V617F-dependent 
Cells 
 
Introduction 
Statins are a class of drugs used to treat hypercholesteremia because 
they inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol 
biosynthesis. Statins have made profound impacts on improving the morbidity 
and mortality of cardiovascular disease [134, 223-227]. Statin drugs are well 
tolerated by patients and are safe and affordable [168]. As of 2012, there were 
seven statins on the market and include both synthetic and naturally 
(fermentation) derived compounds.  These statins include: atorvastatin 
(synthetic), fluvastatin (synthetic), pitavastatin (synthetic), rosuvastatin 
(synthetic), lovastatin (naturally derived), simvastatin (naturally derived), and 
pravastatin (naturally derived) [136]. Although the complete mechanism by which 
statins lower cardiovascular risk remains to be determined [153], many groups 
have contributed insight into the complex actions of statins in the cardiovascular 
setting. In general, statins have been shown to reduce cholesterol [228], inhibit 
protein prenylation, induce vascular remodeling through inhibition of NFkB and 
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matrix metalloproteinases [229], and elicit anti-inflammatory effects by modifying 
C-reactive protein, tumor necrosis factor-alpha, serum amyloid A, and brain 
natriuretic peptide levels [153, 230-232]. Importantly, statins have been shown to 
block growth and induce apoptosis of multiple types of cancer cells in vitro and in 
vivo [153], including; glioma, melanoma, prostate cancer, neuroblastoma, and 
leukemia [172, 217, 233-237]. Our recent studies, described in Chapter 2, 
demonstrated that statins have a selective cytotoxic effect in JAK2-V617F-driven 
MPN model cells.  
 Our novel findings implicated cholesterol-rich lipid rafts as having a 
potentially important role in the dysregulated JAK2/STAT5 signaling induced by 
the JAK2-V617F mutant, suggesting lipid rafts may serve as a platform for 
signaling complexes required for JAK/STAT signaling. Our work has shown that 
cholesterol-lowering statins are cytotoxic and thus growth inhibitory in JAK2-
V617F-driven cell lines and primary MPN cells [238]. We had aimed to disrupt 
lipid rafts with cholesterol-lowering statins by targeting cholesterol biosynthesis 
and thus deregulating a crucial component of lipid rafts. However, HMG-CoA 
reductase inhibition by statins could have multiple effects in cells (i.e. inhibition of 
protein prenylation and, or lowering cellular cholesterol), since this enzyme is an 
early component in the mevalonate pathway.  Thus, it is plausible that cholesterol 
biosynthesis may not be the only or the actual cause of the cytotoxic effects 
induced by statins in JAK2-V617F driven cells. 
 In this study, we analyzed the mechanism of action driving the cytotoxic 
effects induced by statins in JAK2-V617F-driven cells. We demonstrate that 
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multiple components of the mevalonate pathway are affected by statin treatment 
in MPN cells including: cholesterol levels, geranylgeranylation, and farnesylation.  
In addition, we show that JAK2 localization in rafts, and EpoR glycosylation are 
also altered upon statin treatment of MPN model cells. We have systematically 
assessed the mevalonate pathway end products that may contribute to the 
cytotoxic effects in JAK2V617F-driven cells. Our results suggest a likely 
requirement of multiple components of the mevalonate pathway for JAK2-V617F-
driven cell growth.  
 
Results 
Assessing the contribution of cholesterol in statin-induced effects on 
JAK2V617F-dependent cells 
 We began analyzing the mechanism of action driving the cytotoxic effects 
of statins by assessing the cholesterol levels after treatment with cholesterol-
lowering statins. Multiple statins at 1 and 5 µM doses were effective at reducing 
the cholesterol levels in HEL cells. A reduction in cholesterol was seen after 96 
hours of treatment by simvastatin (sim), lovastatin (lov), and atorvastatin (ator) 
compared to the DMSO control in HEL cells (Figure 14). Specifically, we found 
an 18.3% (1 µM sim), 37.8% (5 µM sim), 16.8% (1 µM lov), 46.9% (5 µM lov), 
46.9% (1 µM ator), and 41.2% (5 µM ator) reduction in cholesterol compared to 
the DMSO control in HEL cells (Figure 14).  
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Cholesterol add-back after statin treatment in JAK2-V617F-driven cells 
 We next performed add-back experiments in order to determine if 
cholesterol addition could restore cell growth and viability after simvastatin 
treatment. We supplemented our cell cultures with Synthechol, a synthetic 
cholesterol, and assessed viable cell numbers over time by trypan blue 
exclusion.  
There was a minor degree of cytotoxicity associated with 0.1X and 1X cholesterol 
add back itself to SET-2 cells when compared to DMSO control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescence 
Units 
(Relative 
Cholesterol) 
Figure 14: Statins reduce cholesterol in HEL cells. (A) A fluorescent-
based cholesterol assay was used to measure cholesterol in HEL cells 
that were treated with 1 or 5 µM statin (simvastatin (sim), lovastatin (lov), 
or atorvastatin (ator)) for 96 hours. (B) The percent cholesterol reduction 
compared to DMSO-treated cells is graphed. Low dose statins (1 and 5 
µM) were able to reduce cellular cholesterol compared to the DMSO 
control.  
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However, we found a partial restoration in total viable SET-2 cell numbers 
over time with the addition of cholesterol during 5 µM simvastatin treatment 
(Figure 15A). The % viability of SET-2 cells treated with 5 µM sim was slightly 
greater after two days of cholesterol treatment, while after four days of treatment 
the % viability was not enhanced (Figure 15B). Cholesterol addition in HEL cells 
was toxic so we were unable to utilize these cells for these analyses (data not 
shown). 
 
Evaluating the effects of statins on lipid rafts and JAK2 localization in lipid rafts 
Our previous studies showed that lipid raft disrupting agents such as 
MBCD (methyl-beta-cyclodextrin) and filipin complex, downregulated 
JAK2/STAT5 signaling in cell lines that were dependent on the transforming 
JAK2-V617F mutant (Chapter 2) [238]. To address the potential of statins to 
disrupt lipid rafts in JAK2-driven cells, we evaluated the effect of atorvastatin on 
lipid raft integrity in SET-2 cells. Detergent resistant membranes (DRMs) were 
isolated using a gradient-ultracentrifugation technique. DRMs were assessed by 
dot blot analysis, detecting GM1, a lipid raft-associating lipid using cholera toxin-
HRP as a probe. Separation between the upper and lower fractions suggests that 
the lower buoyant density lipid rafts separated from the higher buoyant density 
whole cell lysate.  
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Figure 15: Cholesterol add back partially restores the cytotoxic 
effects induced by simvastatin in SET-cells. (A) SET-2 cells were 
treated with 0 (DMSO), 5 µM simvastatin (sim), 1X cholesterol, or 5 µM 
sim with 1X cholesterol and counted every two days by trypan blue 
exclusion. Addition of 5 µM sim and 1X cholesterol resulted in a partial 
increase in viable cell numbers compared to the 5 µM sim treatment 
alone. (B) The viability of SET-2 cells was assessed after 5 µM sim and 
cholesterol addition and compared to DMSO control and 5 µM sim alone. 
Cholesterol addition with 5 µM sim slightly enhanced the viability at Day 2 
compared to the 5 uM sim alone sample. At day 4, no restoration in 
viability was seen under the same conditions. Experiments were 
replicated three times. Error bars indicate standard deviation and p value 
was calculated using T-test (GraphPad Prism, Inc.). 
  
65 
 
We found that 5 µM atorvastatin did not disrupt lipid rafts as shown by the 
detection of GM1 in the low buoyant density raft fraction (primarily fraction 2), 
which is separated by fractions 3 and 4, making fractions 5 and 6 the non-raft 
fractions (Figure 16A). In support of the dot blot data, we analyzed Flotillin-1, a 
resident raft protein, by western blot and detected Flotillin-1 in the lower buoyant 
density fractions (2 and 3) in the 5 µM ator treated SET-2 cells, similar to the  
DMSO control (Figure 16B), suggesting there was no noticeable disruption in 
lipid rafts (Figure 4B). Nevertheless, when assessing the expression of JAK2 
across the fractions, we did find less JAK2 in the DRM (fraction 2 and 3) in the 1 
and 5 µM ator treated SET-2 cells compared to the DMSO control (Figure 16B). 
This suggests JAK2 protein localization within DRMs had been affected by statin 
treatment. Similar results were seen with 5 µM simvastatin in SET-2 cells (data 
not shown). We previously reported that statins reduced the localization of JAK2-
V617F and lipid rafts as shown by immunofluorescence (Chapter 2) [238], but did 
not significantly reduce lipid raft aggregates, which is in support of our raft 
fractionation data showing atorvastatin did not fully disrupt lipid rafts but lowered 
JAK2-V617F detection in the lipid raft fractions (Figure 12).  
 
Mevalonate restores the cytotoxic effect of statins in JAK2-V617F-driven cells   
To address the multiple end products, aside from cholesterol, in the 
mevalonate pathway, we performed add back experiments with intermediates of 
the mevalonate pathway to simvastatin treated JAK2-V617F-driven cell lines and 
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Figure 16: Atorvastatin alters JAK2 localization in detergent resistant 
membranes. (A) SET-2 cells were treated with 0 (DMSO), 1, or 5 µM 
atorvastatin (ator) for 96 hours and were analyzed similarly to the experiment in 
Figure 8A by density gradient separation, where lower buoyant density raft 
fractions were separated from higher buoyant density non-raft fractions. Dot 
blot analysis demonstrates GM1 detection in fraction 2 in DMSO control, with 
GM1 detected in fraction 2 in the 5 µM ator sample, suggesting lipid rafts were 
not fully disrupted.  (B) Western blot analysis from gradient fractionation lysates 
was performed similarly to experiment in Figure 8B. Total JAK2 and Flotillin-1 
were blotted, as indicated. Flotillin-1, a resident raft marker, is detected in lower 
buoyant density raft fractions (2-4), suggesting lipid rafts were not fully 
disrupted. However, reduced JAK2 is detected in the 5 µM ator sample, 
suggesting alteration of JAK2 localization in lipid rafts.  
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assessed the effects on the total viable cell numbers over time. We started with 
an early intermediate in the mevalonate pathway, mevalonate, which is the 
product of HMG-CoA reductase reducing HMG-CoA (refer to Figure 6). 
Mevalonate (100 µM) restored the total viable cell number of HEL cells treated 
with 1 and 5 µM sim (Figure 17). 
 
Assessing the role of farnesylation in statin action in targeting JAK2-V617F-
driven cells 
 
Further downstream the pathway is the end product, farnesyl. The first 
method we employed to detect potential inhibition of farnesylation involved 
probing samples for cleavage of HDJ-2, a protein that is exclusively farnesylated. 
Western blot analyses of HDJ-2 can distinguish the farnesylated form (lower 
molecular weight, ~44 kDa) and the unfarnesylated form (~49 kDa) of HDJ2. 
Inhibition of farnesylation results in an increase in the presence of the upper 
band and thus results in a double band by western blot due to detection of the 
unfarnesylated HDJ-2 protein. Higher doses (5 µM or higher) of sim or lov 
displayed a minor induction of the unfarnesylated HDJ-2 protein band, while both 
1 and 5 µM ator displayed a single band for HDJ-2, suggesting little to no 
inhibition of farnesylation (Figure 18A). As a positive control for farnesylation 
inhibition, we treated HEL cells with 1 µM FTI-2153 for 48 hours and assessed 
HDJ-2 by western blot. The HDJ-2 doublet validated that farnesylation was 
inhibited (Figure 18A). 
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To investigate the possibility that farnesylpyrophosphate (FPP) could 
restore the minor inhibition on farnesylation we detected with 5 µM simvastatin 
and 5 µM lovastatin, we treated HEL cells with 5 µM simvastatin and 10 µM FPP 
for 48 hours and assessed HDJ-2. Western blot analyses showed that FPP did 
restore HDJ-2 farnesylation as demonstrated by the single HDJ-2 band (Figure 
18B), suggesting FPP is functional and warrants use in studies that aim to 
reverse the cytotoxic effects of simvastatin. 
 
Farnesylpyrophosphate does not readily restore viable cell numbers after statin 
treatment in JAK2-V617F-driven cell lines   
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Figure 17: Mevalonate restores cytotoxic effects induced by simvastatin 
in HEL cells. HEL cells were treated with 0 (0.1% DMSO and 0.1% 
methanol), 100 µM mevalonate (Mev), and 1 or 5 µM simvastatin (sim) alone, 
or in combination with 100 µM Mev were counted every two days using trypan 
blue exclusion. Mev prevented the cytotoxic effect of sim treatment. Data 
represents a single experiment that was replicated three times. 
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Although we detected only a minor inhibition of farnesylation after 
simvastatin treatment, we sought to rule out the possibility that statins cytotoxic 
actions were due to targeting farnesylation to any extent. To restore the defect in 
farnesylation we added back farnesylpyrophosphate (FPP) to HEL cells treated 
with 5 µM simvastatin and found there to be a partial restorative effect on total 
viable cell numbers (Figure 19A) and viability over time (Figure 19B), suggesting 
that FPP does not readily prevent the cytotoxic effects on viable cell numbers 
and viability induced by 5 µM simvastatin in HEL cells.  
 
Effects on geranylgeranylation after statin treatment in JAK2-V617F-driven cells 
 
To investigate components further downstream of FPP in the mevalonate 
pathway, we assessed the state of geranylgeranylation after statin treatment in 
HEL cells. We used Rap1A protein as a tool to gauge geranylgeranylation, for it 
is exclusively geranylgeranylated. Using an antibody that recognizes the Rap1A 
carboxy terminus, which gets cleaved after geranylgeranylation, and thus this 
antibody only recognizes unprenylated Rap1A protein. We demonstrated that 
sim, lov, and ator induced the accumulation of unprenylated Rap1A. This 
demonstrated clear inhibition of geranylgeranylation. As a control to induce 
unprenylated Rap1A protein, we utilized the geranylgernanyl transferase inhibitor 
GGTI-2417 (Figure 20A). Furthermore, we reversed the inhibition on 
geranylgeranylation with geranylgeranylpyrophospahte (GGPP) as shown by 
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Figure 18: Statins induce a minor inhibition on farnesylation in HEL 
cells. (A) HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin (sim), 
lovastatin (lov), or atorvastatin (ator) for 48 hours. Western blot analysis of 
HDJ-2, a protein that is exclusively farnesylated, showed that statins induced 
minor inhibition of farnesylation as shown by the appearance of the double 
band (unprenylated and prenylated HDJ-2). HEL cells were also treated with 
1 µM FTI-2153 (farnesyl transferase inhibitor) as a positive control for 
inhibition of farnesylation. (B) Western blot analysis of HEL treated with 
farnesylpyrophosphate (FPP) and 5 µM sim for 48 hours demonstrated 
restoration in HDJ-2 farnesylation (single band indicates active farnesylation), 
suggesting FPP add back does restore minor farnesylation defects induced 
by sim. 
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Figure 19: Farnesylpyrophosphate (FPP) partially restores cytotoxic 
effects induced by simvastatin in HEL cells. (A) HEL cells were treated with 
0 (DMSO), 5 µM simvastatin (sim), and 10 µM FPP alone or in combination 
with 5 µM sim and counted with trypan blue. FPP addition with 5 µM sim 
resulted in a slight restoration in total viable HEL cells over time. (B) The 
viability of growth curve samples was analyzed (# of live cells/# of total cells) 
and showed that FPP in combination with 5 µM sim partially restored cell 
viability compared to 5 µM sim alone. Error bars represent standard deviation 
and p value calculated using T-test (GraphPad Prism, Inc.). Experimental data 
represents a single experiment which was replicated three times, with 
replicates supporting presented data. 
  
72 
 
western blot analysis of Rap1A in HEL cells treated with 5 µM simvastatin and 10 
µM GGPP for 48 hours (Figure 20B). 
 
 GGPP partially restores total viable HEL cells treated with simvastatin after 48 
hours of treatment, with loss of any restorative effect at 96 hours 
To determine if the inhibition of geranylgeranylation was responsible for 
statin’s cytotoxic effects, we performed experiments adding back geranylgeranyl 
pyrophosphate (GGPP) to statin treated HEL cells and assessed viable cell 
numbers over time. Interestingly, GGPP could not restore cell growth (Figure 
21A). However, the viability of HEL cells treated with simvastatin was restored 
after 48 hours of treatment with GGPP add back, but at the 96 hour time point 
and beyond, no restorative effect was observed (Figure 21B).  
 
Assessing the role of combined prenylation defects in statin action in targeting 
JAK2-V617F-driven cells 
 To address the effects on combined prenylation, both farnesylation and 
geranylgeranylation, after statin action in JAK2-V617F-driven cells, we performed 
add back experiments restoring GGPP and FPP simultaneously and used trypan 
blue exclusion analysis to determine viable cell numbers. The combination of 10 
µM GGPP and 10 µM FPP co-cultured with 5 µM simvastatin treated HEL cells 
did not improve total viable cell numbers compared to the 5 µM simvastatin and 
10 µM FPP treated sample, or the 5 µM simvastatin and 10 µM GGPP sample 
(Figure 22). 
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Figure 20: Statins inhibit geranylgeranylation in JAk2-V617F-dependent 
cells.  (A) HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin 
(sim), lovastatin (lov), or atorvastatin (ator) for 48 hours and analyzed by 
western blot to assess inhibition of geranylgeranylation by probing with an 
antibody that recognizes the carboxy terminus of Rap1A, which gets cleaved 
after geranylgeranylation. We treated HEL cells with 10 µM GGTI-2417 
(geranylgeranyl transferase inhibitor) for 48 hours, as a positive control for 
geranylgeranylation inhibition (presence of band indicates inhibition). Sim, 
lov, and ator inhibited geranylgeranylation. Hsp90 was detected as a loading 
control. (B) To test if the inhibition on geranylgeranylation could be reversed 
with geranylgeranylpyrophosphate (GGPP), we ran western blot analysis of 
HEL cells treated with 0 (DMSO), 5 µM sim alone, and 10 µM GGPP alone or 
in combination with 5 µM sim and by probing for Rap1A. GGPP restored the 
inhibition of geranylgeranylation induced by simvastatin. Actin was detected 
as a loading control. 
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Figure 21: GGPP addition can not restore HEL cell growth and viability 
following simvastatin treatment. (A) HEL cells were treated with 0 (DMSO), 
5 µM simvastatin (sim), 10 µM GGPP, alone or in combination with 5 µM sim 
and counted with trypan blue. GGPP does not restore viable HEL cell numbers 
over time. (B) Analysis of the viability of HEL cells treated with sim, GGPP 
alone, or in combination demonstrated that viability was restored at short-time 
points (Day 2), but restorative effect was lost at later time points (Day 4). Error 
bars represent standard deviation of duplicate samples. Data represents 
experiments that were run a minimum of three times. 
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The effect of simvastatin on EpoR glycosylation 
 
Hamadmad et al. previously reported lov treatment at short-time points 
could downregulate surface expression of EpoR in ASE2, an erythroleukemia cell 
line [203]. Hamadmad et al. demonstrated that lov treatment inhibited 
geranylgeranylation and dolichol, a downstream intermediate off of the 
geranylgeranyl branch of the mevalonate pathway involved in N-linked  
glycosylation with proteins like EpoR (refer to Figure 6). Furthermore, due to 
EpoR potentially playing an important role in PV and because JAK2-V617F 
requires a homodimeric cytokine receptor to function, we questioned if 
simvastatin and its ability to inhibit geranylgeranylation, affected EpoR 
glycosylation. After treating HEL cells with 5 µM simvastatin for 48 hours, we 
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Figure 22: Restoration of prenylation in simvastatin treated HEL cells 
does not restore viable cell numbers. HEL cells were treated with 0 
(DMSO), 5 µM simvastatin (sim), 10 µM GGPP, and 10 µM FPP alone and in 
combination as indicated, and counted with trypan blue. Add back of both 
prenylation end products, FPP and GGPP, did not restore viable cell numbers 
when compared to the 5 µM sim and DMSO controls. This suggests that 
overall prenylation may not be solely responsible for the cytotoxic effects 
induced by sim. Data represents a single experiment that was run in triplicate. 
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found a difference in the expression pattern of EpoR by western blot analysis. 
HEL cells treated with DMSO control displayed a two-band protein banding 
pattern with a ~66 kDa (mature, fully gycosylated form) and ~64 kDa (maturing 
form) band (Figure 23; lane 1), while the 5 µM sim treated sample displayed a 
prominent ~64 kDa (maturing form of EpoR) with possible breakdown products of 
EpoR between 34 and 43 kDa (Figure 23; lane 3). We have confirmed that the 
~66kDa form is fully gylcosylated because of its resistance to deglycosylation by 
EndoH (data not shown), a characteristic of full glycosylation. The ~66kDa fully 
gycosylated form is utilized as a surrogate for plasma membrane localized EpoR 
and thus sim treatment appears to inhibit plasma membrane localization of 
EpoR. We were also able to confirm that restoring geranylgeranylation with 10 
µM GGPP after 5 µM sim treatment in HEL cells did restore the expression of the 
~66 kDa EpoR band (mature form) (Figure 23; lane 4).  
 
Discussion 
Statin drugs have recently developed an appreciated potential in the treatment of 
some cancers including melanoma [239], glioma [240], neuroblastoma [241], 
prostate cancer [170, 242-243], and leukemia [234, 244]. We were the first to 
report on the anti-neoplastic effects of statins in JAK2-V617F-driven 
myeloprolifertaive cell lines and primary MPN samples [238]. The complete 
mechanism of action behind statin activity in the hypercholesteremia setting is 
still not fully elucidated. Statins have been shown to have a multitude of effects  
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Figure 23: Simvastatin alters expression of EpoR gycosylation forms in 
HEL cells. HEL cells were treated with 0 (DMSO), 10 µM GGPP, and 5 µM 
simvastatin (sim) alone, or in combination with 10 µM GGPP for 48 hours and 
were analyzed by western blot to assess EpoR expression. Sim treatment 
promoted an accumulation of the 64 kDa EpoR form (partially glycosylated, still 
maturing form) whereas, the DMSO control displayed the fully glycosylated EpoR 
(~66 kDa) and the maturing EpoR form (64 kDa), suggesting sim blocked EpoR 
from becoming fully glycosylated. Sim also induced potential breakdown products 
of EpoR with detection of multiple bands ranging in molecular weights from ~20-
56 kDa. To test the effects of reduced GGPP and subsequent loss of dolichol, 
GGPP was co-cultured with 5 µM sim treated HEL cells for 48 hours and 
analyzed by western blot to investigate EpoR glycosylation isoforms. GGPP 
restored the fully glycosylated EpoR isoform (~66 kDa). 
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that contribute to lowering cholesterol in cardiovascular risk patients [134, 153, 
224, 226-227]. Variability of statin action can be influenced by cell type, disease 
type, type of statin, dosage, and duration of treatment [245]. In this work, we 
further investigated the statin mechanism of action in the setting of JAK2-V617F-
driven transformation.  Indeed, 1 and 5 µM doses of all statins tested (sim, lov, 
and ator) that induced cytotoxic effect in JAK2-V617F-driven cell lines reduced 
cholesterol to variable capacities depending on the statin and dose. Since our 
previous work showed a dependence of JAK2-V617F signaling on lipid rafts, we 
initially chose to treat the JAK2-V617F-dependent MPN model cell lines with 
statins in an attempt to alter lipid rafts, which are rich in and are dependent on 
cholesterol. Statins, like lipid raft disrupting agents we hoped would alter plasma 
membrane cholesterol and hence disrupt lipid rafts, the site where JAK2-V617F 
protein complexes may be located. Although our data did not provide evidence 
that 5 µM ator disrupted lipid rafts, we did find decreased JAK2 protein in the raft 
fractions, suggesting that JAK2 protein and lipid raft co-localization was 
disrupted. Considering the percentage of cholesterol reduction after atorvastatin 
treatment (46% reduction after 96 hours of treatment), in comparison to lipid raft 
disrupting agents, which are thought to drastically alter cholesterol, statins may 
not disrupt lipid rafts enough to the level of detection in the lipid raft isolation 
assay. Nonetheless, we demonstrate evidence for an alteration in JAK2 protein 
localization with lipid rafts, but no direct evidence for lipid raft disruption by 
atorvastatin treatment. Interestingly, cholesterol add back allowed for only a 
partial restoration in total viable SET-2 cells over time, suggesting that the 
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cholesterol decrease may not be solely responsible for the cytotoxic effects 
induced by statins.  It is important to note that few reports that attempt to analyze 
statin affects by adding back products of the mevalonate pathway ever 
demonstrate that cholesterol add back is successful. In fact, personal 
communication with other researchers has confirmed that cholesterol addition 
can be toxic to cells, as we have seen when elevated cholesterol addition is used 
[246]. These results lead us to examining potential effects on end products other 
than cholesterol in the mevalonate pathway. 
We first took a step back and added an early intermediate of the 
mevalonate pathway, mevalonate itself.  Mevalonate is produced by the activity 
of HMG-CoA reductase and thus its levels should be decreased following 
treatment with statins, which are inhibitors of HMG-CoA reductase (Figure 17).  
Indeed, mevalonate completely rescued the growth inhibitory effects of statin 
treatment, demonstrating that, the HMG-CoA reductase inhibitory activity of 
statins is responsible for the detrimental effects observed on JAK2-V617F-driven 
cell growth (Figure 17). 
Since statin treatment clearly inhibited geranylgeranylation (Figure 20) we 
also performed GGPP add back experiments. GGPP add back had a slight 
restorative effect on the viability of HEL cells in the short-term but not the long-
term (Figure 21).  Indeed, simvastatin inhibited geranylgeranylation in these 
JAK2-V617F-driven cells, but GGPP add back could not restore growth, 
suggesting that inhibition of geranylgeranylation is not solely responsible for the 
cytotoxic effect induced by simvastatin. Perhaps the initial cell death induced by 
  
80 
 
simvastatin is due to geranylgeranylation inhibition but additional effects of 
inhibiting the mevalonate pathway cannot be overcome by GGPP, and this leads 
to the inability of GGPP to restore long-term growth and viability. This is not 
inconsistent with other published work, which suggests GGPP add back can 
rescue the effect of statin treatment. Such data are generally always presented 
as short-term experiments and never address long-term effects such as the 
ability to restore cell growth. Additionally, simvastatin elicits a minor inhibition of 
farnesylation (Figure 18). Combination add back of the isoprenoid intermediates 
FPP and GGPP, was also unable to fully restore cell growth and viability after 
simvastatin treatment, suggesting statin’s cytotoxic effect is not based on 
inhibiting prenylation alone. However, the inhibition of geranylgeranylation was 
shown to be responsible for the redistribution of the glycosylated forms of EpoR, 
shifting the EpoR protein population to the immature glycosylated isoform. 
Adding back GGPP restored fully processed/glycosylated (plasma membrane 
localized) EpoR (Figure 23). Since JAK2-V617F requires a cytokine receptor for 
signaling, this could be a mechanism by which statins may affect JAK2-V617F 
signaling, that is, statins may regulate the processing and subsequent plasma 
membrane localization of a requisite cytokine receptor. However, in the cell lines 
we have utilized, the specific requirement for EpoR remains unknown, but it is 
possible the glycosylation of other receptors may be similarly affected by statin 
treatment. Because mevalonate completely protected cells from the effects of 
statin treatment (Figure 17), we conclude that the effects of statins are indeed 
due to its inhibition of the mevalonate pathway. However, since isoprenoid 
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intermediate add back did not protect cells from the effects of statin treatment, it 
is likely that inhibition of other pathways or a combination of pathways that are 
dependent on products of the mevalonate pathway are responsible for the effect 
of statins on JAK2-V617F-driven cell growth.     
In summary, we have shown statins affect multiple components of the 
mevalonate pathway, including inhibition of cholesterol biosynthesis, 
geranylgeranylation, and a minor inhibition of farnesylation, in MPN model cells 
that are dependent on JAK2-V617F. Statins presumably inhibit the various end 
products of the mevalonate pathway and induce a variety of cellular changes. 
These changes may no longer be reversible or occur at a rate that is not 
compatible with add back of the end products, as we were unable to identify a 
single end product whose inhibition could be determined to elicit the effects of 
statin treatment. While the exact mechanism by which statins induce its cytotoxic 
effects on JAK2-V617F-positive MPN model cells remains to be elucidated, it is 
clear that these cells are sensitive to statins by undergoing apoptosis which 
results in decreased cell growth. This suggests statin treatment may be an option 
to incorporate into future therapies for MPNs, including possible combination with 
JAK2 inhibitors.     
 
Materials and Methods 
Growth curves 
HEL or SET-2 cells were plated at a concentration of 0.1 – 0.25 X 106 
cells/mL and treated with 0 (DMSO), and 1 or 5 µM simvastatin (Sigma-Aldrich 
  
82 
 
#S6196).  1X synthechol (Sigma-Aldrich # S5442), 100 µM mevalonate (Sigma-
Aldrich #79849), 10 µM FPP (Sigma-Aldrich # 6892), and 10 µM GGPP (Sigma-
Aldrich #G6025) were added alone, or in combination (DMSO content maintained 
at 0.1% across all samples) and cell counts and viability were assessed every 
two days using trypan blue. Cell cultures were passed every two days with 
replenishment of additive lipid compounds, ensuring the stability of these lipids is 
not a concern in the experiments. 
 
Cholesterol assay 
Cholesterol was measured using Amplex Red Reagent as described in 
Chapter 2 [238]. Briefly, 2 – 3 X 106 cells were treated with 0 (DMSO), 1 or 5 µM 
simvastatin (Sigma-Aldrich #S6196), lovastatin (Sigma-Aldrich #M2147), or 
atorvastatin (Sigma-Aldrich #PZ0001) for 96 hours. Cells were washed with 1X 
RT PBS three times and ficolled with lymphocyte separation media (Corning #25-
072-CV) to remove dead cells. Amplex Red Cholesterol Measurement kit 
(Invitrogen #A12216) was used to measure cholesterol as manufacture 
recommends. Fluorescence was measured using Synergy HT fluoremeter 
BioTek Inc. Winooski, VT, USA) using 560/590 excitation/emission settings. 
 
Western blot 
2 – 5 X 106 cells were washed with 4ºC 1X PBS and lysed in 4ºC lysis 
buffer (25 mMTris, pH=7.4, 150 mM NaCl, 25 mM NaF, 1% Triton-X-100, and 
protease inhibitors). Cell lysate was centrifuged at 14.5 X 105 X g for 5 minutes at 
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4ºC. Pierce BCA reagent (Thermo Scientific) was used to determine protein 
concentration. Protein lystaes were run on SDS-PAGE (8 - 12.5% gels). Primary 
antibodies included: total JAK2 (Cell Signaling Technology #3230), Rap1A 
(Santa Cruz #sc-1482), HDJ-2 (Neomarker #AM00209PU-N), Hsp90 (Santa Cruz 
#sc-7947), actin (Sigma #AC-74), EpoR (Amgen A82), Flotillin-1 (Cell Signaling 
Technologies #3253), and CTB-HRP (Sigma-Aldrich #C3741). Secondary 
antibodies were from Thermo Scientific. West Pico Chemilluminescence, ECL 
Plus, or West Femto Chemilluminescence were used to develop western blots. 
DRM dot blot and western blot analyses performed in same fashion as described 
in Chapter 2 [238]. 
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Chapter 4 
Statins cooperate with JAK inhibitors to enhance the killing effect on JAK2-
V617F-driven cells 
 
Introduction 
The classical MPNs including polycythemia vera (PV), essential 
thrombocythemia (ET), and primary myelofibrosis (PMF), are hematopoietic stem 
cell disorders characterized by expansion of the myeloid lineage in one form or 
another [186]. Dysregulated JAK/STAT signaling is common to the classical 
MPNs [65, 95], with activating mutations found in patients including mutations in 
cytokine receptors (i.e. MPL-W515) [78-79], JAK2 (i.e. JAK2-V617F [186], exon 
12 mutations [74]) as well as inactivating mutations in negative regulators of 
JAK/STAT signaling (e.g. SOCS1, LNK, etc.) [64].  
The JAK inhibitor, ruxolitinib (Incyte, INCB018424) was recently approved 
for the treatment of MF in November of 2011. Ruxolitinib induced a marked 
reduction in splenomegaly and reduced in constitutional symptoms including 
fever, fatigue, cachexia, night sweats, anemia, pruitus, and bone pain [247]. 
However, JAK inhibitors have not been shown to induce partial or complete 
remissions, nor have they been shown to reduce allele burden in MF patients 
[94, 205], suggesting there is much room for improvement in the treatment of 
MPN patients. It is well established that JAK/STAT signaling is defective in MPNs 
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[65], and it is plausible that targeting multiple sites in a key, dysregulated 
pathway may be necessary to effectively block oncogenic signaling.  
We have demonstrated that cholesterol-lowering statins reduce total 
viable cell numbers and induced apoptosis in JAK2-V617F-driven cell lines and 
inhibit colony formation of primary MPN cells (Chapter 2). In our current study, 
we hypothesized that statins will enhance the cytotoxic effect of JAK2 inhibition 
on JAK2-V617F-dependent cells. We demonstrate an enhancement of cytotoxic 
effects when combining statin therapy with JAK inhibitor therapy in JAK2-V617F-
driven cells. We show statin and JAK inhibitor combination treatment enhances 
the reduction in total viable cell numbers and viability over time compared to 
single agent treatment alone. Additionally, we show that combination treatment 
amplifies the number of cells undergoing apoptosis compared to single agent 
treatment. Furthermore, we found that combination treatment led to a G1 arrest 
in the cell cycle. Our work is the first to provide evidence that statins drugs 
cooperate with JAK inhibitors in JAK2-V617F-driven cells and proposes statins 
may enhance JAK inhibitor therapy in patients. 
 
Results 
 To determine if there is a potential therapeutic advantage to combining 
statin treatment with JAK inhibitors, we treated a panel of JAK2-V617F-driven 
MPN model cells. These cell lines include HEL (Human Erythroleukemia) cells, 
homozygous for the JAK2-V617F mutation, SET-2 cells, heterozygous for the 
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JAK2-V617F mutation, and Uke1 cells, homozygous for the JAK2-V617F 
mutation [196].  
 
Simvastatin cooperates with JAK Inhibitor I to enhance the reduction in viable 
HEL cells 
HEL cells treated with simvastatin or JAK Inhibitor I (JI), a pan JAK 
inhibitor, were effective at reducing total viable cell numbers as single agents, but 
in combination led to an enhanced reduction in total viable cell number over time 
(Figure 24A). Calculated fold reductions comparing treated samples to DMSO 
control (DMSO total viable cell number/drug-treated sample total viable cell 
number = fold reduction) were also graphed (Figure 24B). HEL cells treated with 
1 µM sim alone showed no reduction in total viable cells compared to DMSO 
control at day 4, whereas 1 µM JI led to a 11.7 fold reduction. Combination of 1 
µM sim and 1 µM JI resulted in 17.5 fold reduction in total viable cells. Likewise, 
5 µM sim alone resulted in a 1.9 fold reduction at day 4, while combining 5 µM 
sim with 1 µM JI led to a 50.9 fold reduction in total viable HEL cells (Figure 24B). 
Interestingly, the 1 µM JI sample after eight days of treatment demonstrated 
signs of resistance with increases in the total viable cell numbers (Figure 24A). 
However, JI combined with only 1 µM simvastatin eliminated resistance from 
occurring (Figure 24A).  
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Figure 24: Simvastatin cooperates with JAK Inhibitor I in HEL cells to 
enhance the reduction in total viable cell numbers. (A) HEL cells were 
treated with DMSO (0.1% dimethyl sulfoxide), low dose simvastatin (sim), and 
JAK Inhibitor I (JI) alone, and in combination and counted every two days 
using trypan blue exclusion. Low dose sim and JI alone reduce total viable cell 
numbers, but when combined led to an enhanced reduction in cell numbers 
over time. (B) Graph represents total viable cell fold reduction of drug treated 
samples compared to DMSO control at day 4 (Equation: (DMSO total viable 
cell number/ sample total viable cell number = fold reduction). Experimental 
data represents a single experiment which was replicated in SET-2 cells 
(Figure 25). 
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Simvastatin cooperates with JAK Inhibitor I to enhance the reduction in viable 
SET-2 cells 
Similarly, in a second JAK2-V617F-dependent cell line, SET-2 cells, 
displayed a 2 fold reduction in total viable cell numbers in response to 5 µM 
simvastatin treatment after 4 days of treatment (Figure 25A). 5 µM simvastatin  
alone, led to a 2 fold reduction, while, 1 µM JI led to a 11.9 fold reduction at day 
4. When combined, these two drugs induced a 23.7 fold reduction in total viable 
cells after 4 days and this reduction continued to increase over additional days of 
culture.  Impressively, 5 µM sim with 1 µM JI led to 83 fold reduction in total 
viable cells compared to DMSO control (Figure 25B). These data demonstrate 
that the cooperative ability of simvastatin and JAK Inhibitor I are not JAK2-
V617F-positive cell line dependent, as both HEL (Figure 24) and SET-2 (Figure 
25) cells responded similarly. 
 
 Simvastatin cooperates with INCB018424 to enhance the reduction in viable 
HEL cells 
 To test the potential of a second JAK inhibitor to cooperate with statins, 
we tested the effects of the JAK1/2 inhibitor, INCB018424 (424, ruxolitinib) 
combined with statin treatment on total viable cell numbers and % viability as 
demonstrated by trypan blue exclusion. Concordant with the HEL data, 1 µM 
simvastatin combined with 0.25 µM 424 led to a similar decrease in total viable 
HEL cell numbers (Figure 26A) (5.6 fold reduction) as 0.5 µM 424  
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Figure 25: Simvastatin cooperates with JAK Inhibitor I in SET-2 cells to 
enhance the reduction in total viable cell numbers. (A) SET-2 cells were 
treated with DMSO, low dose simvastatin (sim), and JAK Inhibitor I (JI) 
alone, and in combination and counted every two days using trypan blue 
exclusion. Low dose sim and JI alone reduce total viable cell numbers, but 
when combined lead to an enhanced reduction in cell numbers over time. 
(B) Graph represents total viable cell fold reduction comparing drug treated 
samples to DMSO control on day 4. Experimental data represents a single 
experiment which was replicated in HEL cells (Figure 24). 
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treatment alone (5.9 fold reduction) (Figure 26B). Enhanced fold reductions were 
seen when combining 1 µM sim (1.6 fold reduction alone) with 0.5 µM 424 (5.9  
fold reduction alone), resulting in a 10.9 fold reduction in viable cells. Enhanced 
growth inhibition of the culture was especially apparent in later time points of the 
experiment (e.g. day 10). 
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Figure 26: Simvastatin cooperates with INCB018424 in HEL cells to 
enhance the reduction in total viable cell numbers. (A) HEL cells were 
treated with low dose simvastatin (sim) or INCB018424 (424) alone, or in 
combination and were counted every two days using trypan blue. Combination 
treatment of sim and 424 lead to an exaggerated reduction in total viable cell 
numbers over time, in a dose-dependent manner. (B) Replicate growth curve to 
26A.  
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C. 
 
 
 
 
 
 
 
 
 
 
 
 
Simvastatin cooperates with INCB018424 to enhance the reduction viable SET-2 
cells 
SET-2 cells displayed similar enhanced cytotoxic effects with the 
combination of simvastatin and INCB018424 treatment as shown by the 
reduction in total viable cell numbers (Figure 27A). SET-2 cells treated with 1 µM 
sim resulted in a subtle 1.4 fold reduction in viable cells at day 4, while 0.25 µM 
424 led to a 3.1 fold reduction. Combining 1 µM sim with 0.25 µM 424 gave rise 
to an enhanced 5 fold reduction at day 4. Again, combining 1 µM sim with 0.5 µM 
424 (4.5 fold reduction with 0.5 µM 424 alone) resulted in an 8.8 fold reduction in 
viable cells at day 4 (Figure 27B).  
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Figure 26 (continued): Simvastatin cooperates with INCB018424 in 
HEL cells to enhance the reduction in total viable cell numbers. 
(C)Graph represents total viable cell fold reduction of drug treated samples 
compared to DMSO control on day 4. Experimental data represents a 
single experiment which was replicated in SET-2 cells (Figure 27), and 
multiple statins (Figure 28 & 29), with replicates supporting presented 
data. 
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Figure 27: Simvastatin cooperates with INCB018424 in SET-2 cells to 
enhance the reduction in total viable cell numbers. (A) SET-2 cells were 
treated with low dose simvastatin (sim) or INCB018424 (424) alone, or in 
combination and were counted every two days using trypan blue. Combination 
treatment of sim and 424 lead to an exaggerated reduction in total viable cell 
numbers over time, in a dose-dependent manner. (B) Graph represents total 
viable cell fold reduction of drug treated samples compared to DMSO control 
at day 4. Experimental data represents a single experiment which was 
replicated in HEL cells (Figure 26), and multiple statins (Figure 28 & 29), with 
replicates supporting presented data. 
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Lovastatin cooperates with INCB018424 to enhance the reduction in viable HEL 
cells 
We next wanted to determine if other statins had similar effects on JAK2-
V617F-driven growth. We tested the ability of a second statin to cooperate with 
INCB018424. We found that lovastatin combined with INCB018424 also 
exaggerated the reduction in total viable HEL cell numbers (Figure 28A). 1 µM  
lovastatin led to a 1.6 fold reduction in total viable cell numbers, while 0.25 or 0.5 
µM 424 led to a 2.8 or 5.9 fold reduction. Combining 1 µM lov with either 0.25 µM 
or 0.5 µM 424 resulted in an enhanced 5.6 or 7.5 fold reduction, respectively 
(Figure 28B).  
 
Atorvastatin cooperates with INCB018424 to enhance the reduction in viable 
HEL cells 
We investigated the potential cytotoxic effects of a third statin. Atorvastatin 
and INCB018424 combination treatment yielded an enhanced reduction in total 
viable cell numbers compared to single agent treatment (Figure 29). 1 µM 
atorvastatin led to a 2.3 fold reduction, while 0.25 µM 424 led to a 2.8 fold 
reduction in viable cell numbers at day 4. Combination treatment of 1 µM 
atorvastatin and 0.25 µM 424 resulted in a 5.4 fold reduction in viable cell 
numbers (Figure 29C).  
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Figure 28: Lovastatin cooperates with INCB018424 in HEL cells to 
enhance the reduction in total viable cells. (A) HEL cells were treated with 
low dose lovastatin (lov) or INCB018424 (424) alone, or in combination and 
counted every two days using trypan blue. Lov combined with 424 resulted in 
an enhanced reduction in total viable cells. (B) Graph represents total viable 
cell fold reduction of drug treated samples compared to DMSO control at day 
4. Experimental data represents a single experiment which was replicated with 
multiple statins (Figure 26 & 29), with replicates supporting presented data. 
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Figure 29: Atorvastatin cooperates with INCB018424 in HEL cells to 
enhance the reduction in total viable cell numbers. (A) HEL cells were 
treated with low dose atorvastatin (ator) or INCB018424 (424) alone, or in 
combination and counted every two days using trypan blue. Ator combined with 
424 resulted in an enhanced reduction in total viable cells. (B) Graph 
represents total viable cell fold reduction of drug treated samples compared to 
DMSO control at day 4. Experimental data represents a single experiment 
which was replicated using multiple statins (Figure 26 & 28), with replicates 
supporting presented data. 
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Statins cooperate with INCB018424 to enhance apoptosis in JAK2-driven cells 
 To assess the effects of simvastatin and INCB018424 combination 
treatment on apoptosis, we analyzed the Annexin V-positive cell population by 
flow cytometry. HEL cells were treated with 1 and 5 µM simvastatin alone and in 
combination with 0.25 and 0.5 µM INCB018424 for 24 and 48 hours, and 
assessed for Annexin V binding. Combination treatment of simvastatin and 
INCB018424 gave rise to an even greater percentage of the cell population that  
was positive for Annexin V, compared to single agent treatment (Figure 30A).  
This is especially obvious for combination of 5 µM simvastatin and 0.5 µM 
INCB018424. Similar results were obtained with atorvastatin and INCB018424 
treatment in HEL cells (Figure 30B). 
 
Simvastatin combined with INCB018424 treatment induces a G1 arrest in JAK2-
V617F-driven cells 
 To determine the effect of combination treatment with simvastatin and 
INCB018424 on the cell cycle in our MPN model cell lines, we stained cells with 
propidium iodide (P.I.) and analyzed DNA content by flow cytometry. We 
normalized the P.I. values (% of population) for each sample to the DMSO 
control by calculating the difference between the DMSO control and each sample 
to report the change in the % of cell population in each cell cycle phase (G1, G2, 
or S). After 24 hours of treatment we found a 4.22% increase in G2 after 5 µM 
simvastatin treatment. 424-treated cells displayed an increase of cells in G1 of 
11.77% and 16.47% in the 0.25 and 0.5 µM 424-treated samples, respectively. 
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Figure 30: Statins cooperate with INCB018424 to enhance apoptosis in 
JAK2-V617F-dependent HEL cells.  (A) HEL cells were treated with simvastatin 
(1 and 5 µM sim), or INCB018424 (0.25 and 0.5 µM 424) alone, or in 
combination for 24 or 48 hours and stained with Annexin V and analyzed by flow 
cytometry. Sim combined with 424 led to an enhanced induction of apoptosis in a 
dose and time-dependent manner. Error bars represent standard deviation of 
duplicate samples. (B) Combining atorvastatin (ator) with 424 after 24 or 48 
hours led to an increase in Annexin V-positive HEL cells in a dose and time-
dependent manner.  Experimental data represents a single experiment which 
was replicated and preformed with multiple statins (Figure 30B), with replicates 
supporting presented data. P value was calculated using unpaired t-test using 
GraphPad Prism software. 
Combination treatment of 5 µM simvastatin with either 0.25 µM 424 or 0.5 µM 
424 led to an additional increase in cells arrested in G1 (Figure 31), even though 
simvastatin alone did not induce G1 arrest. 
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Bliss additivity model demonstrates cooperation between simvastatin and 
INCB018424 
 Next, we sought out to define the type of drug cooperation between statins 
and INCB018424 treatment in HEL cells. Specifically, we wanted to determine if 
the two drugs acted in an additive or synergistic manner. We assessed the  
cooperativity between simvastatin and INCB018424 in HEL cells after 72 hours 
of treatment using the Bliss additivity model [248]. We created a three-
dimensional growth inhibition surface that was delineated by the single drug dose 
curves (Figure 32A). The Bliss additivity plane was calculated using the equation 
Icomb = (IA + IB) – (IA * IB), where Icomb is the theoretical inhibition due to drugs A 
and B in combination and IA and IB are the observed inhibition due to each 
individual drug. We then calculated the 95% confidence interval and added 
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Figure 31: Simvastatin enhances the INCB018424-induced G1 cell cycle 
arrest. HEL cells were treated with DMSO, 5 µM simvastatin (sim), or 0.25 or 
0.5 µM INCB018424 alone and in combination for 24 hours and stained with 
propidium iodide and analyzed by flow cytometry. Combination treatment led 
to a dose-dependent increase in cells arrested in G1. Experimental data 
represents a single experiment. 
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(upper limit) or subtracted (lower limit) this value from the theoretical plane to 
relay statistical significance to our observed values. Values above the upper 95% 
confidence interval are synergistic and a sum of these values found to be greater 
than 1 suggests moderate synergy between two drugs. The sum of our observed 
values (Figure 32B, upward cones) was found to be 0.43. Values below the lower 
95% confidence interval are antagonistic and a sum of these values found to be 
less than -1 suggests moderate antagonism. The sum of these values (Figure 
32C, downward cones) was found to be -0.32. All other data points are between 
these two planes and are considered additive.   
The Bliss value of 0.43 suggests simvastatin cooperates with INCB018424 
in an additive manner in HEL cells. However, we did identify potential doses and 
combinations that may be synergistic, as well as antagonistic using the lower 
95% confidence interval (Figure 32C). We found that the combination of 1.250 
µM simvastatin and 0.15 µM INCB018424 showed potential synergism, while 
0.3125 µM simvastatin combined with 0.039 µM, 0.15 µM, or 0.625 µM 
demonstrated potential antagonism (Figure 32C). 
 
Simvastatin reduces total viable Uke1 cells that persist in the presence of 
INCB018424 
A recent report by Koppikar et al. has demonstrated that cells dependent 
on JAK2-V617F (Uke1 and SET-2 cell lines) can persist in the presence of  
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Figure 32: Simvastatin 
cooperates with 
INCB018424 in an additive 
manner. (A) HEL cells treated 
with 0 (DMSO) to 20 µM 
simvastatin (sim) alone, or in 
combination with 0 (DMSO) to 
10 µM INCB018424 (424) for 
72 hours were analyzed for 
cell viability using Promega 
CellTiter Glo luminescence. 
Graph plots growth inhibition 
of sim versus 424. (B) Bliss 
additivity model was used to 
determine Bliss values. The 
plane at 0 represents the 
upper 95% confidence 
interval. Upward cones 
represent statistically relevant 
synergistic values, while 
downward cones represent 
values below the 95% 
confidence interval. (C) Bliss 
values using lower 95% 
confidence interval. 
Downward cones represent 
statistically relevant 
antagonistic values, while 
upward cones represent 
values above the lower 95% 
confidence interval. 
Simvastatin cooperates with 
424 in an additive manner, as 
suggested by the Bliss Value 
of 0.43. However, we 
identified doses with potential 
synergism at 1.25 µM sim and 
0.15 µM 424. This experiment 
was done with assistance 
from Uwe and Lily Rix (Moffitt 
Cancer Center). 
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INCB018424 [249]. The term persistence is used rather than resistance because 
if the INCB018424 is removed from culture for a short period of time and re-
introduced, the cells become sensitive to the drug again. We investigated the 
effect simvastatin would have on Uke1-Persistent (Uke1-P) viable cell numbers 
over time.We created Uke1-P cells by treating Uke1 cells with low doses of 
INCB018424 (0.1 µM) and selecting cells that grow out, subsequently increasing 
the doses to 1 µM until a population of cells grows in the presence of 1 µM 424. 
Sim (5 µM) prevented the outgrowth if Uke-P cells over the course of the 8 day 
experiment (Figure 33). 
 
Discussion 
It is accepted in the MPN field that activation of JAK/STAT signaling is a 
key feature among all classical MPN patients [65]. Inhibitors that target JAK 
enzymes have recently been approved to treat MF patients because of the 
improved effects on splenomegaly and constitutional symptoms [94, 205], 
suggesting benefit in targeting JAKs in patients. Additionally, the COMFORT-1 
and 2 JAK inhibitor clinical trials demonstrated that regardless of presence of the 
JAK2-V617F mutant, patients responded similarly to ruxolitinib (INCB018424) 
[29, 93-95], suggesting again that JAK activity is important in MPNs. More 
recently, we were the first to report that statins alone induce cytotoxic effects in 
JAK2-V617F-dependent cell lines and primary MPN cells (Chapter 2) [238].  In 
our current study, we sought out to determine if JAK inhibitor therapy cooperated 
with statin therapy in JAK2-V617F-dependent cells to ultimately identify  
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additional therapeutic strategies for MPN patients. Indeed, we now provide 
evidence of the cooperation between statins and JAK inhibitors.  
Our studies showing that multiple statins cooperate with multiple JAK 
inhibitors in multiple JAK2-V617F-dependent cell lines are novel. We 
demonstrate that statins cooperate with JAK inhibitors to enhance the reduction 
in total viable cell numbers and viability compared to the single agents alone 
(Figures 1-6). These data are relevant and intriguing for the current MPN field.  
First, the results from the two phase 3 clinical trials involving INCB018424 
(ruxolitinib), COMFORT-1 and COMFORT-2, did show that some patients did 
better than others and it is still poorly understood why that is the case. A key 
finding from the clinical trials with JAK2 inhibitors is that these inhibitors do not 
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Figure 33: Simvastatin reduces total viable Uke1 cells that persist in the 
presence of INCB018424. Uke1 cells were made persistent to 1 µM 
INCB018424 (424) by treating Uke1 cells with low doses (starting dose 0.1 µM 
424), selecting for cells that grew out, and increasing the concentration of 424 
up to 1 µM. Cells were then treated with 5 µM simvastatin (sim) for 8 days and 
counted using trypan blue. 5 µM sim prevented the outgrowth of Uke-P cells 
growing in the presence of 1 µM 424. Experimental data represents a single 
experiment which was replicated three times, with replicates supporting 
presented data. 
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decrease allele burden [94, 205].  That is, they do not get rid of the neoplastic 
MPN cells in patients.  Therefore, an approach that enhances the efficacy of 
MPN cell death in response to therapy is still needed in order to induce remission 
in MPN patients. Second, it has been proposed that combination therapies of 
JAK2 inhibitors and other agents may play a major role in future MPN therapies 
[116-117]. For example, studies have shown cooperation between JAK2 
inhibition and Hsp90 inhibitors as well as HDAC inhibitors on MPN cells.  We 
believe our studies suggest that statins may be another option for combinatorial 
therapeutics with JAK2 inhibitors. 
Importantly, we showed in two separate cases, with two separate JAK 
inhibitors that statins are still effective at inducing cytotoxic effects in our JAK2-
V617F-driven cells that show signs of resistance. First, we show that after eight 
days of treatment, HEL cells become resistant to the pan JAK inhibitor, JAK 
Inhibitor I, Simvastatin treatment blocked the ability of the HEL cells treated with 
JAK Inhibitor I to acquire resistance (Figure 24A). Second, we showed that low 
dose simvastatin (5 µM) was effective at inhibiting the growth of Uke1-persistent 
cells. These cells persistently grow in the presence of INCB018424, suggesting 
that resistance or persistence to the JAK inhibitor does not also provide 
resistance to the cytotoxic effects of simvastatin (Figure 33). Since some MPN 
patients are resistant to the current standard of care (ex. Hydroxyurea) [29, 93, 
95], we question if statins can provide therapeutic benefit in these cases. We 
propose statins may provide benefit in MF or other MPN patients resistant or 
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persistent to therapy, contributing to the management of the high peripheral cell 
burden. 
Further investigations are underway to determine the effect of combining 
statin and JAK inhibitor on MPN cells. In collaboration with Ross Levine 
(Memorial Sloan Kettering Cancer Center) we are utilizing an MPN mouse model 
to determine if statins alone or in combination with JAK2 inhibition can inhibit 
MPN formation in vivo. We will also be performing colony formation assays with 
primary mononuclear cells from JAK2-V617F-positive MPN patients treated with 
statins combined with 424.  
Our assessment of the type of cooperation exhibited between statins and 
INCB018424 demonstrated an additive cooperation. We did identify potential 
dose combinations of statins (1.25 µM simvastatin combined with 0.15 µM 
INCB018424) that may be synergistic, and we are currently investigating this 
prospect further. It is important to consider that the Bliss cooperation analyses, 
are short-term experiments, 72-96 hours, whereas the growth curve experiments 
run between 192-264 hours and is where we can observe a significant effect of 
statins. It will be interesting to determine if differences in the length of time of 
experiments affects synergy designation. 
Our studies described in this chapter are the first to demonstrate the 
cooperation between JAK inhibitors and statins in JAK2-V617F-dependent cells. 
We show that multiple statins cooperate with multiple JAK inhibitors in multiple 
JAK2-V617F-dependent cells. We propose that statins combined with JAK 
inhibitor therapy in patients may lead to an improved response compared to JAK 
  
105 
 
inhibitor therapy alone. Statins may provide an affordable, safe therapeutic 
addition to JAK-targeted therapy for MPN patients. 
 
Materials and Methods 
Growth curves 
HEL, SET-2, Uke-1, or Uke1-P cells were plated at a concentration of 0.1 -
0.25 X 106 cells/mL and treated with 0 (dimethyl sulfoxide (DMSO)), 1 or 5 µM 
simvastatin (Sigma-Aldrich #S6196), lovastatin (Sigma-Aldrich #M2147), 
atorvastatin (Sigma-Aldrich #PZ0001), 1 µM JAK Inhibitor I (Calbiochem 
#420097), or 0.25 - 0.5 µM INCB018424 (Chemietek) alone, or in combination, 
maintaining the DMSO content to 0.1% across all samples. Treated cells were 
counted every two days with trypan blue using a hemocytometer. Cells were split 
every two days, refreshing drugs and media. 
 
Annexin V staining 
HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin or 
atorvastatin, alone, or in combination with 0.25 - 0.5 µM INCB018424 
(Chemietek) for 24 or 48 hours. 1 X 106 cells were washed with 1X PBS (room 
temperature (RT)) and reconstituted in 100 µL of 5% BSA. 0.5 X 106 cells (50 µL) 
were added to 50 µL 2X binding buffer (BD Biosciences), 8 µL [10 µg/mL] 
propidium iodide (P.I.) (BD Biosciences), and 3 µL Annexin V-FITC (BD 
Biosciences #556570), and incubated for 15 minutes at RT in the dark. 300 µL of 
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1X binding buffer (BD Biosciences) were added and stained cells were analyzed 
by flow cytometry (Calibur 2). 
 
Cell cycle analysis 
1 X 106 HEL cells were treated with 0 (DMSO), 1 or 5 µM simvastatin or 
atorvastatin, alone, or in combination with 0.25 – 0.5 µM INCB018424 
(Chemietek) for 24 or 48 hours. Cells were washed with 1X, RT PBS and 
resuspended in 1X PBS. 900 µL of ice-cold 70% ethanol was added to 100 µL of 
cells in PBS in a drop-wise fashion and vortexed on low speed. Cells were 
incubated overnight at -20º C. After overnight incubation, samples were thawed 
on ice and subsequently centrifuged at 14.5 X 105 X g for 60 seconds. Cells were 
washed with 1X cold PBS and resuspended in 500 µL of (0.1% Triton-X-100-PBS 
+ 10 µg/mL P.I. + 1 mg RNase A). Incubated sample in the dark for 30 minutes at 
RT and analyzed by flow cytometry. 
 
Bliss cooperation 
HEL cells were treated with 0 (DMSO) to 20 µM simvastatin (Sigma 
Aldrich #S6196) or 0 (DMSO) to 10 µM INCB018424 (Chemietek), alone or in 
combination, in 384 well dishes at a plating confluency of 0.1 X 105 cells/mL. 
Treatment incubations included 24, 48, and 72 hours at 37º C and 5% CO2. 
DMSO content was maintained at 0.4% across all samples. Cell viability was 
determined using Promega CellTiter Glo luminescence (Promega #G7571). 
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Synergy was determined using % viability inhibition values and calculated using 
the Bliss addivitity model [248]. 
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Chapter 5 
Summary, Final Discussion, and Future Work 
 
 
Summary and Discussion 
 
Our work has provided multiple novel discoveries for the MPN field. First, 
JAK2-V617F, a key etiologic factor for MPN development, is localized to lipid 
rafts (Chapter 2). Second, JAK2-V617F signaling is dependent on lipid rafts 
(Chapter 2). Third, MPN cells dependent on JAK2-V617F are sensitive to statin 
treatment (Chapters 2 and 4). Fourth, statins cooperate with JAK2 inhibitors to 
inhibit the growth and induce apoptosis of JAK2-V617F dependent cells (Chapter 
4).  
We have demonstrated that the localization of the JAK2-V617F mutant to 
cholesterol-rich lipid rafts may be important for the full transforming potential of 
this oncogene. Disruption of lipid rafts with agents that alter membrane 
cholesterol reduced the localization of JAK2-V617F protein in lipid rafts (Figure 8 
and 9). We found that multiple cholesterol alteration agents are effective at 
downregulating JAK2/STAT signaling induced by JAK2-V617F (Figures 10A and 
10C, respectively).  
Currently, there are no lipid raft disrupting agents on the market for use in 
humans, so to investigate functional aspects of targeting lipid rafts in JAK2-
V617F-driven MPN cells, we utilized the statin class of drugs. The JAK2/STAT 
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pathway is accepted as being crucial to MPNs and is therefore an appreciated 
target for therapeutic intervention [65]. We hypothesized that cholesterol-lowering 
statins may disrupt lipid rafts and hence, disrupt the JAK2-V617F signaling 
complex at the membrane, ultimately attenuating JAK2/STAT signaling. Indeed, 
cholesterol lowering statins downregulated JAK2/STAT signaling, inhibited cell 
growth, and induced apoptosis in JAK2-V617F-dependent cells (Figure 10, 
11A/B, and 12A/B, respectively). Very importantly, the cytotoxic effect of statins 
was not only seen in MPN model cell lines, but primary JAK2-V617F-positive 
MPN cells were also sensitive to low dose statin treatment.  
Additionally, since JAK2 inhibitors alone are ineffective at reducing the 
allele burden in MPN patients and thus fail to induce remission, the cooperativity 
between statins and JAK2 inhibitors we have observed is highly relevant to a 
need in the MPN field, that is, enhanced therapeutic killing of MPN cells. 
Combination treatment with statins may provide opportunities to sensitize MPN 
cells to JAK2-targeted therapy. This additional treatment, whether it is directed at 
JAK2 signaling or not, may also decrease the development of de novo or innate 
resistance that has been seen in MPN patients. Such a combination treatment 
may also decrease the rate at which MPN patients transform to AML.   
 An important aspect to our work involves the dosage used in our 
experiments. Our in vitro experiments are within physiological range that could 
be tolerated in humans. Studies surrounding lovastatin showed that patients can 
tolerate ~3.9 µM without any toxicities long-term [250]. It has also been shown 
that patients given higher concentrations, ~12 µM for short time points (7 days) in 
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cycles show no toxicity complications [250]. Another strategy has been employed 
to avoid toxicity in patients given high doses of statins, whereby the cholesterol 
precursor, squalene is supplemented, allowing patients to tolerate higher statin 
doses [251]. Further investigation is needed to determine any implications of 
therapeutic benefit with chronic concentrations such as these in MPNs.   
In summary, we hypothesize that statins promote a cytotoxic effect in 
MPN cells, and propose that statins, as a mono-therapy or more provocatively in 
a combinatorial approach with JAK2 inhibitors, may provide an effective 
therapeutic approach to improve the lives of MPN patients (Figure 34).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MPN cell cytotoxicity
downregulation of JAK/STAT signaling
Proposed Model
opportunity to sensitize 
cells to JAK2 inhibitor 
therapy?
statins cholesterol protein 
prenylation
or ?
Figure 34: Proposed model for targeting the mevalonate pathway with 
statins in conjunction with JAK2 inhibitors in MPNs. 
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Future Work 
 
 We believe the work presented in this dissertation encourages additional 
studies focused on investigating the potential role of lipid rafts in JAK2 signaling 
in MPNs and the use of statins in novel therapeutic strategies for MPNs. We 
intend to further investigate the role of lipid rafts in signaling driven by mutations 
other than JAK2-V617F. Mutations of particular interest include JAK2 exon 12, 
MPL, and LNK mutations. In addition, we would like to address the role of 
cytokine receptors to further understand the sensitivity of JAK2-V617F signaling 
to lipid raft alteration. For example, we are interested in comparing the sensitivity 
to lipid raft disruption in the setting of EpoR/JAK2-V167F (important in PV) 
versus MPL/JAK2-V617F (important in ET) versus GCSF-R/JAK2-V617F 
(important in MF). This is of particular interest because the JAK2-V617F mutant 
requires the expression of a cytokine receptor and these receptors may play 
important roles in MPNs. We will also analyze the effects of statins alone, and in 
combination with JAK2 inhibitors in JAK2-V617F-driven MPN murine models. In 
addition, we will expand our studies with primary patient samples to determine 
the extent to which statins cooperate with JAK2 inhibition in both JAK2-V617F-
positive and negative patient cells. With encouraging results from these and 
other experiments, a clinical trial addressing statins in MPN therapy will be a 
possibility in the near future.  
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